GLP Generic: when cheaper GLP-1 drugs arrive, country by country

The Cheapest Semaglutide Is a Legal Question Before It Is a Price Question

2026-11-01T00:00:00+00:00

In India, as of October 8, 2026, the lowest stated monthly price for generic semaglutide was 1,290 rupees (roughly $15), for vials from Natco and Eris. In the United States, the 2024 list price of Ozempic was $959 for a 30-day supply. Same molecule. The difference is not chemistry. It is mostly law.</p>

So if you typed “cheapest semaglutide” into a search engine, the honest answer has two halves. Globally, the cheapest legal semaglutide is generic, and as of September 2026 it was on sale in India, Canada, Brazil, South Africa and Saudi Arabia. In the US no generic is on sale, and the lowest legal prices belong to the brand: Novo Nordisk’s self-pay price for Wegovy started at $149 a month for the pill and $199 a month for the pen as of October 21, 2026, and the Medicare negotiated price of $274 per 30-day supply takes effect January 1, 2027.</p>

Where the cheapest semaglutide is sold, and why there</h2>
Novo Nordisk filed its core semaglutide compound patent on March 20, 2006. Patents last 20 years, so in markets without extensions the patent ended on March 20, 2026. In India it lapsed that day, and on March 21 more than 40 generic brands launched. Monthly prices went from 8,800 to 11,175 rupees for Ozempic (roughly $100 to $130) to 1,800 to 4,200 rupees for generics (roughly $20 to $50).</p>
Novo noticed. Within about ten days it cut Ozempic’s Indian price by 36% and Wegovy’s by 48%. Generics still took 50% of India’s semaglutide sales by value in April 2026. Canada got there by a stranger road (a lapsed patent and an unpaid maintenance fee), which the site covers elsewhere.</p>
In the US, the compound patent, US 8,129,343, got a 1,040-day patent term extension, pushing it to December 5, 2031. Novo’s 2025 Form 20-F says 2032 is the effective compound expiry for Ozempic, Rybelsus and Wegovy, and secondary patents run to 2038. I would rather not think too hard about what the patent lawyers have scheduled for the years between 2032 and 2038.</p>

The legal routes that exist in the US today</h2>
There are not many, and they all run through the patent holder or the government. One is the brand’s own self-pay price, the $149 and $199 figures above. Another is Medicare, which put Ozempic, Rybelsus and Wegovy into the second round of drug price negotiation under the Inflation Reduction Act. The result is $274 per 30-day supply, which is a 71% reduction from the $959 list price. That is a big number delivered in a federal register sort of voice (which is the only voice the federal register has, and it uses it for everything).</p>
Then there is compounding, where US pharmacies sold injectable semaglutide for an average of $230 a month, and where industry groups won court injunctions that, in the words of one legal explainer, “temporarily prevented a complete shutdown” of FDA enforcement against 503B outsourcers. That is a different site’s subject, and also a different legal theory (compounding is not generic entry, and nobody involved pretends it is).</p>

The generic that is approved and also not allowed</h2>
On April 10, 2026, Apotex announced the first FDA tentative approval for a generic version of Ozempic, in partnership with Orbicular. Here is what that means in plain words: the FDA looked at the drug, decided it was fine, and told Apotex it may not sell it. That is tentative approval (an extremely bureaucratic form of congratulations). It means the science is done and the patents are not.</p>
The machinery behind this is the Hatch-Waxman Act of 1984, which created both the patent term extension that stretched semaglutide’s patent and the system where a brand company that lists patents in the FDA’s Orange Book can trigger an automatic 30-month stay on generic approval. In some sense the same law gives with one hand and waits with the other. That’s fine; it was designed as a bargain.</p>
Here is a scenario I am making up entirely. A generic company with a tentative approval assigns one employee to watch the calendar. Her whole job is to walk into the CEO’s office every Monday and say “Good news, still approved. Bad news, still 2031.” She does this for five years. She gets a promotion for consistency. She trains a successor, who also watches the calendar, and by December 2031 the company has a small department whose only output is the date. It is like a studio announcing a movie release slot six years out and then hiring people to stare at the poster.</p>

How to read a price that is too good</h2>
Between us, this is the part that matters to anyone staring at a web page with a number on it. The legal US reference points are roughly $149 to $274 a month from the brand and the government, and around $230 on average from compounders. No FDA-approved generic semaglutide is on sale in the US, because the patents have not ended. So any US listing for “generic semaglutide” is describing something other than an approved, launched generic, whatever it calls itself.</p>
The overseas prices are real, but they are prices under Indian or Canadian law, or whatever law applies where the drug is sold. Whether those products can lawfully reach a US buyer is not something the facts here settle, and it is not settled by a low number either.</p>
There is also a ceiling on how cheap legal generics tend to get in America. Prost Biotech notes that US peptide generics typically see only 15% to 40% discounts, versus 80% to 90% for small-molecule generics, “due to the more expensive biosimilar approval pathway.” When Teva launched generic Victoza, it priced a two-pack at $469.60 against roughly $560 for the brand. That’s 16% to 17% off. Even in 2026, with more companies selling it, the average GoodRx price for Teva’s generic liraglutide ran $200 to $450 for a two-pen package and $280 to $750 for a three-pen package. That is what a real, approved, launched US peptide generic looks like on a price page. A US price that beats the brand by 95% is presumably not following that history.</p>

Three ways to read the gap</h2>
There are, roughly, three ways to read the distance between $15 in India and $959 in America.</p>
The first is the patent reading. Price is a function of which calendar you live under. India’s patent ended March 20, 2026, and generics launched March 21. The molecule did not change overnight. The permission did.</p>
The second is the competition reading, where prices fall when the brand feels pressure, not only when generics arrive. Novo cut Wegovy’s Indian price by up to 37% in November 2025, before expiry, and then cut the starting dose by 48% on April 1, 2026. FDA data show generic prices about 39% below brand with one generic producer and more than 95% below with six or more. Brazil just writes it down: the OzemPro Blog says generics there “must be sold at least 35% below the reference product’s price.” Market conditions move both ways, of course. Pharmaceutical Technology reported that Eli Lilly raised the UK price of Mounjaro to “better reflect market conditions,” which is the same sentence pointed in the other direction, lol.</p>
The third reading is the least comfortable. A systematic literature review found prices falling 34% to 93.4% in the one to five years after patent expiry, with lots of variation. Medicare’s negotiation already took 71% off before any generic exists. If US peptide generics land at their usual 15% to 40% discount off a list price, they may arrive in 2032 to find the government got there first. I mean, the stuff about patent cliffs assumes the cliff is the bottom. Anyway, the cheapest legal semaglutide in America, for the foreseeable future, may keep being sold by the company whose patent is the reason it isn’t cheaper.</p>

How Far Do Prices Fall When a Drug Goes Generic?

2026-11-01T00:00:00+00:00

Today the most useful fact about generic drug prices is a pair of numbers from the Food and Drug Administration, and the pair tells you more than either number alone. FDA data, as summarized by DrugPatentWatch, show generics at “approximately 39% below the brand price when there is one generic producer, and more than 95% below the brand price when there are six or more generic producers.” So the honest answer to the title question is that it depends almost entirely on how many companies show up.</p>

That is the plain version. The rest of the evidence fills in timing and product type. A systematic literature review found prices 34% to 93.4% lower in the one to five years after patent expiry, with a lot of variation by country and drug class. Injectable peptides have also tended to fall much less than pills. GLP-1 drugs are injectable peptides whose patents are now expiring around the world, so all three variables apply to them at once.</p>

Why the first generic is only a little cheaper</h2>
Follow the money one link at a time. The brand company gets paid for having a monopoly, and in the US the Hatch-Waxman Act of 1984 helps it keep one: listing patents in the FDA’s Orange Book can trigger an automatic 30-month stay of a generic’s approval. When the first generic finally arrives, it is not competing with forty rivals. It is competing with the brand, which charges a lot.</p>
So what should the first generic charge? It only needs to be cheaper than the brand, and the brand is very expensive. Basically the first generic is playing The Price Is Right in reverse: the winning bid is the one closest to the brand’s price while still being clearly under it. (I assume nobody describes it that way in an actual pricing meeting.)</p>
Here is an invented version of that meeting, clearly made up: “Hey guys, we’re the only generic, the pharmacies will take us at 39% off, why would we offer them 95%?” It is a perfectly reasonable thing to say. It also stops being true the moment a second company gets approved.</p>
The arrangement looks a lot like two gas stations at the same intersection, which tend to price within a few cents of each other because each one’s real competitor is the sign across the street. It is the third and fourth stations that start the price war. Six stations is a commodity.</p>
Other countries build the value of the first slot into law. China’s 2021 patent linkage rules give 12 months of market exclusivity to the first small-molecule generic applicant that invalidates a listed patent and wins approval, and the outlet VCBeat writes that “first generic” status in China “establishes a unique competitive position that is difficult for competitors to shake.” The prize for coming first is being the only generic for a while, which is to say the prize is not having to cut prices very much. The incentive points the wrong way.</p>

How long generic drug prices take to fall</h2>
The review’s range is wide because time is doing most of the work. I feel like the timing question is really a headcount question: how fast do generics two through six arrive?</p>
The US liraglutide story is the slow version. Teva launched the first-ever US generic GLP-1, an authorized generic of Victoza, on June 24, 2024, under a 2019 patent settlement with Novo Nordisk. (An authorized generic is the brand and a generic maker getting into bed together on the terms of the brand’s own competition, which is less exciting than it sounds.) At launch it cost $469.60 for a two-pack against about $560 for the brand, a 16% to 17% discount. Not 95%.</p>
More competition from Sandoz and Viatris was expected from December 2024 onward, and by 2026 GoodRx’s average price range for Teva’s generic two-pen package was $200 to $450. At the low end that is less than half the launch price. At the high end it is roughly the launch price, which is the sort of thing an average range will do to a tidy story.</p>
India is the fast version. Over 40 generic semaglutide brands launched on March 21, 2026, the day after the patent expired. Ozempic had cost 8,800 to 11,175 rupees a month (roughly $100 to $130), and the generics came in at 1,800 to 4,200 rupees (roughly $20 to $50). By October 8, 2026, the lowest stated monthly price was 1,290 rupees (roughly $15), for vials from Natco and Eris.</p>
Forty entrants on day one. That skips the gas stations.</p>
Then the chain grows a link nobody expects. About ten days after the launches, Novo Nordisk cut its Indian price for Ozempic by 36% and for Wegovy by 48%. The brand, whose whole business model was not competing on price, started competing on price, which is the generics doing their job twice: once with their own product and once with the brand’s.</p>

Injectables are not pills, except sometimes legally</h2>
The second variable is what kind of drug it is. According to Prost Biotech, US peptide generic and biosimilar drugs “typically achieve only 15-40% price reductions versus reference products,” compared to 80% to 90% for small-molecule generics, because the biosimilar approval pathway is more expensive. An expensive pathway means fewer companies try. Fewer companies keep you near the 39% end of the FDA curve.</p>
So semaglutide, a peptide, should go through the expensive pathway and fall modestly. Actually, no. The FDA treats peptide chains under 40 amino acids as generic drugs, which puts semaglutide (31 amino acids) and tirzepatide (39) on the generic side of the line, and Apotex received the first US tentative approval for a generic semaglutide injection, through an Abbreviated New Drug Application, announced April 10, 2026. So semaglutide is a peptide that is legally a generic, and whether its US price behaves like a pill’s or like a biologic’s is not settled, because nothing has launched yet to measure. (Tirzepatide clears the line by a single amino acid, which is a very specific thing to have a drug’s pricing depend on.)</p>
Pills, on the other hand, have their own surprise. In India a formulation patent on the SNAC absorption enhancer used in oral semaglutide runs to 2031, blocking generic Rybelsus-type tablets even though the injection is open. Usually the pill is the cheap generic. Here it stays patented.</p>

What happens when a country writes the rule down</h2>
Brazil skips the waiting: generics must by law be sold at least 35% below the reference product’s price, and with several makers the discounts typically reach 50% to 80%. That floor sits close to the FDA’s one-generic number, which I suppose is what a legislature looks like when it writes down the price a lone first generic would have charged anyway and lets the market handle the rest. (I read price-ratio tables for fun, so my sense of what counts as elegant is suspect.)</p>
China had 12 semaglutide generics from 10 companies filed with its regulator by March 20, 2026, some as modified new drugs and some as generic biologics, two routes for one molecule. Canada approved versions from Dr. Reddy’s and Apotex, and a write-up in Legal 500 describes it as a potential “guinea pig” for generic semaglutide pricing, with implications for US importation. To be fair, the US has its own parallel track: semaglutide is in Medicare’s second round of price negotiation, so it may end up with a negotiated price and a generic price, set by two unrelated mechanisms, at about the same time.</p>
The best-studied rule in generic pricing is that the brand’s price falls with each new competitor, and the cleanest test of it this year needed no regulator at all. The most effective drug price regulator in India in 2026 was a calendar, and it only had to work for one day.</p>

Byetta Went Generic First. Nobody Threw a Party.

2026-11-01T00:00:00+00:00

All eight patents listed for Byetta in the FDA’s Orange Book had expired by January 2020. Byetta is exenatide, the original GLP-1 drug in this whole saga, and you might expect that the end of its patents would be a big moment. It was not. Four and a half years later, on August 16, 2024, AstraZeneca permanently discontinued Byetta, and in December 2024 it discontinued Bydureon BCise, the longer-acting exenatide, which one source summarizes as “eliminating the branded reference product.”</p>

So if you typed exenatide generic into a search engine, here is the plain answer the facts allow. Exenatide was the first GLP-1 molecule to run out of listed US patent protection. But nothing in the sources here shows a generic exenatide product launching in the US, and the drug the trade press calls the first generic GLP-1 was liraglutide, in June 2024. In Canada, DrugPatentWatch estimates the generic entry opportunity date for Bydureon at June 21, 2027. Exenatide went generic first in the legal sense and, as far as anyone has documented, not in the pharmacy sense.</p>

Is there an exenatide generic, or did the patents just expire into silence?</h2>
Whether a US generic of Byetta was ever sold is not something these sources settle, and I am not going to guess. What they do settle is the order of events. The patents went first, in 2020. The first generic GLP-1 of any kind came in 2024, and it was a different molecule. Then the exenatide brands were withdrawn.</p>
That is a weird sequence. Usually the story goes patent expires, generics arrive, price falls, everyone writes an article about the cliff. (I write some of those articles, and the cliff metaphor is doing a lot of unpaid labor in them.) Here the patent expired and then, in some sense, the cliff walked away.</p>

The obvious objection: expired patents should mean cheap copies</h2>
The sensible reaction is: a patent is a monopoly with an end date, the end date came, so the monopoly should be over and copies should be everywhere. That is basically how small-molecule pills work. The patent lapses, a dozen manufacturers show up, and the price falls a lot.</p>
That objection is correct about the rule. It is wrong about the incentive. A patent expiring does not make anyone launch anything. It just removes one reason not to.</p>
A generic company has to want the market. And the market for a GLP-1 molecule is not a fixed pie that sits around waiting to be copied. It is presumably shrinking or growing based on whatever newer drug doctors prefer, which is stuff no patent office controls.</p>
Here is a scenario I am inventing. In early 2020 an executive at a generic company stands up in a meeting and says, “Hey team, exenatide is off patent, let’s file.” An analyst builds the model. The model says that if they win, they will own a large share of the exenatide market. Someone asks how big the exenatide market will be by the time they launch. The analyst updates the model. The model now says they will own 100% of a market whose brand has been discontinued, which is a very impressive share of not very much. The executive asks if they can be first-to-file on nothing. The analyst says that is, technically, the easiest exclusivity anyone has ever won.</p>
I don’t know if any meeting like that happened. But the incentive it describes is real, and it explains why the first molecule off patent was not the first molecule to get a celebrated generic.</p>

What the first generic GLP-1 actually was</h2>
The honor went to liraglutide, the drug in Victoza and Saxenda. DiaTribe described Teva’s June 24, 2024 product as “the first-ever US generic GLP-1 drug,” an authorized generic of Victoza launched under a 2019 patent settlement with Novo Nordisk. Hikma then got FDA approval for the first traditional, non-authorized generic liraglutide on December 23, 2024, and launched it in early 2025. On August 28, 2025, Teva launched a generic Saxenda, which Teva called “the first-ever generic GLP-1 indicated for weight loss in the US.” (The site has a whole separate piece on generic Victoza, so I will stop there.)</p>
Notice what the Teva launch was. It was not a patent dying of old age and a generic rushing in. It was a settlement signed in 2019, five years ahead. The first generic GLP-1 was, in a meaningful way, scheduled. The brand company agreed when it would face competition, and on what terms. That is a very orderly way to lose a monopoly. (Most monopolies would like to lose this way, if they have to lose at all.)</p>

Why a generic needs a brand to be generic of</h2>
Let the record reflect the following proposition, which I offer with the full weight of the doctrine: a generic drug is a copy, and a copy presupposes an original. Absent an original, the thing one is producing is not a generic but, strictly speaking, a drug.</p>
That sounds trivial, and it is, but it is the point. The whole generic system is built around referring back to a brand. Even the language is relational. In the EU, the European Medicines Agency says generics can only be marketed once “the marketing protection of the reference product has expired, which is usually 10 or 11 years” from first authorization. The reference product is the anchor. When AstraZeneca discontinued both exenatide brands, the anchor was, in the source’s word, eliminated.</p>
Why did AstraZeneca do it? The sources do not say. One reading is the boring one: the molecule is old, newer GLP-1s exist, and a company does not keep making a product nobody is asking for. The other reading is that a brand with no patents left and a generic future ahead of it has less reason to stick around and defend a shrinking price. Both readings fit the dates. I can’t pick between them.</p>
Either way, the withdrawal arrived about two months after the first generic GLP-1 launched, which was a timely exit. Maybe just in the calendar sense.</p>

What older molecules tell you about the newer ones</h2>
The exenatide story is a useful corrective to the idea that patent expiry is a price event. It is a permission event. Whether it becomes a price event depends on who wants to make the copy, how much the copy costs to make and approve, and whether the original is still worth copying.</p>
That last part matters for how big the discount gets, too. One source estimates that US peptide generics and biosimilars “typically achieve only” 15 to 40% price reductions versus the reference product, compared with 80 to 90% for small-molecule generics, because the approval pathway is more expensive. Treat that as one estimate rather than a law of nature. (Laws of nature in drug pricing are rare, and the ones that exist are usually patented.) But if it is roughly right, it means even the GLP-1s that do get copied will not collapse in price the way an old blood pressure pill does. That’s fine as an expectation. It is just not the cliff people picture.</p>
Now compare semaglutide, which is the molecule everyone actually cares about. Health Canada approved Dr. Reddy’s generic semaglutide on April 28, 2026, with eight other submissions under review at the time. Brazil’s core patent expired March 20, 2026 and its first generic approval followed in May. South Africa got a launch in August 2026 with 13 more applications pending. China, meanwhile, rewards the first successful patent challenger with 12 months of market exclusivity, and VCBeat says that “first generic” status there establishes a position that is “difficult for competitors to shake.” That is what a fought-over molecule looks like. Lots of filers, lots of countries, lots of lawyers or whatever.</p>
Exenatide got none of that crowd. It is the Super Bowl ticket bought for the year after the team relocated. Technically valid. Nobody in the stands.</p>
The pattern, anyway, is that the race to copy a drug is a measure of how much people still want the original. Extend that one step and you get an uncomfortable test for the newer drugs: the clearest sign that semaglutide has fully gone generic will not be a pile of approvals but a short notice, years from now, saying its maker has stopped making it.</p>

Generic Semaglutide in India: The 2026 Cliff

2026-11-01T00:00:00+00:00

For a while, an Indian court let Indian drugmakers manufacture semaglutide in India and sell it almost anywhere in the world except India. Then, on March 21, 2026, the “except India” part expired, and so did a lot of prices.</p>

That is the short answer for anyone searching generic semaglutide india. Novo Nordisk’s compound patent on semaglutide lapsed in India on March 20, 2026, and generic injectable versions went on sale the next day. Branded Ozempic had been selling for ₹8,800 to ₹11,175 a month (roughly $100 to $130), and the generics arrived at ₹1,800 to ₹4,200 (roughly $20 to $50). The pill version is a separate matter and stays blocked until 2031.</p>

The sentence, read like a contract</h2>
Here is the sentence I want to read slowly. MedPath, reporting on the litigation, wrote that “The Delhi High Court allowed Dr Reddy’s and OneSource Specialty Pharma to export semaglutide to countries where Novo Nordisk does not hold patent protection, while prohibiting domestic Indian sales until March 2026.” It is an ordinary sentence in a news story. It is also, read as if it were a contract, a pretty complete description of how a patent cliff works in a country that makes drugs for export.</p>
Start with “allowed.” You only get allowed to do something somebody was trying to stop. Novo held an Indian patent on the molecule, and a patent is, in some sense, a legal right to make other people ask permission. The court gave some permission. Not all of it.</p>
“Dr Reddy’s and OneSource Specialty Pharma.” Two companies, named. Not “the Indian generics industry,” which would show up later in force. (The headline on that story also mentions a challenge to the validity of Novo’s patent; the sentence I am reading does not say how that came out, and I won’t guess.)</p>
“To export semaglutide.” This is the interesting verb. A patent is national, and the court’s answer, as reported, was that the making could happen here as long as the selling happened somewhere else.</p>
“To countries where Novo Nordisk does not hold patent protection.” This looks like a list of countries. It is actually a list that changes on known dates. Novo’s core compound patent was filed on March 20, 2006, which gives a baseline 20-year expiry of March 20, 2026 anywhere nobody extended it. So the set of countries Dr. Reddy’s could ship to was, basically, a set that was scheduled to get much bigger on one specific Friday.</p>
“While prohibiting domestic Indian sales.” The one market the product definitely could not reach was the market of the country where the companies are based. (The sentence does not say where the factories are.)</p>
“Until March 2026.” The prohibition had an expiry date, and it was the patent’s expiry date. So the court did not really decide whether India would get cheap semaglutide; the calendar had already decided that. The court decided what the Indian companies were allowed to do while they waited.</p>
They waited very efficiently.</p>

What generic semaglutide in India looked like on day one</h2>
By the time the date arrived, the companies were not starting from scratch. In January 2026, Sun Pharmaceutical, Zydus Lifesciences and Alkem Laboratories received approval in India to manufacture and sell generic versions of Wegovy and Ozempic. Companies that announced launches on or before March 21 include Dr. Reddy’s, Sun Pharma, Zydus, Torrent, Alkem, Glenmark, Natco, Eris and USV.</p>
How many showed up on day one? The tracker Generic Guide says generic semaglutide arrived “with more than a dozen manufacturers launching on day one.” That’s a clean number. Actually, it isn’t clean, which is the more interesting fact: one compilation counts “over 40 generic semaglutide brands” launching on March 21, while a six-month review counted 12 makers publicly selling 20 brands as of October 8. Those are different things being counted (manufacturers, brands, announcements versus public launches), and the sources do not reconcile them. What is settled is that the answer is “a lot,” on the same morning, for the same molecule.</p>
Here is an invented scene, clearly made up. A pharmacist on March 20 stocks one semaglutide pen and knows its price. On March 21 she has a dozen boxes from a dozen companies, all with the same active ingredient and different logos, and by the time she has alphabetized them two more sales reps arrive, each explaining (truthfully) that the molecule is identical and (hopefully) that their box is nicer. By June she is running the shelf like a fantasy football draft, tracking injury reports on supply. By October she needs a spreadsheet to tell her which of twenty brands is cheapest this week. It is Natco or Eris, at ₹1,290 a month for vials (roughly $15), as of October 8.</p>

Novo’s response, and why everyone did the sensible thing</h2>
Within about ten days of the launches, Novo Nordisk cut the price of Ozempic in India by 36% and Wegovy by 48%. Price cuts like this are, formally, voluntary.</p>
You can see why each party behaved the way it did. Novo, facing twenty brands of its own molecule, can either keep its price and watch the volume leave, or cut and keep some of it; every week at the old price is a week of patients and pharmacies learning the generic names. The generic makers, selling something that is by design the same as everyone else’s, have basically one thing to compete on, which is the number on the box (Dr. Reddy’s was reported in February 2026 as hoping to launch up to 60% below Wegovy). And patients and payers, offered the same molecule for a fraction of the price, behave like people offered the same molecule for a fraction of the price.</p>
The April numbers show the result in two ways that look contradictory and aren’t. Generics were 137,000 of 170,000 injectable semaglutide units sold in India, or about 4 in 5. By value they were ₹44 crore of an ₹88 crore market (that’s roughly $5 million of roughly $10 million), or exactly half. Four-fifths of the units, half the money. That’s fine; that is just what “cheaper” means when you write it as a market share. (One source calls April “two months after patent expiry,” which is generous counting, since the expiry was March 20.)</p>
I mean, you could picture the meeting. “Hey guys, so the price we’ve been defending since launch, we’re going to take about half of it off, effective now.” Nobody in that meeting is surprised. The date was on the patent.</p>

Why the export clause matters more after the cliff</h2>
On the other hand, the domestic market is now a place where twenty brands fight over a price that keeps falling. The export clause from the court sentence starts to look like the real prize. As of September 2026, generic semaglutide was on sale in India, Canada, Brazil, South Africa and Saudi Arabia. Health Canada approved Dr. Reddy’s generic on April 28, 2026 (the Canadian patent lapsed over an unpaid fee, which is a story for another article). Brazil refused Novo a patent term extension and approved its first generic in May. Saudi Arabia, where no local patent was reported, saw its first generic launch on September 16.</p>
Where those exported pens are actually made, the sources here do not settle, and I won’t pretend they do. But the logic of the court’s sentence is that the list of “countries where Novo Nordisk does not hold patent protection” is the addressable market for anyone in India with an injectable line, and the list is published in advance. One analysis sorts it into waves: 2026 for India, China, Brazil, Canada and South Africa; around 2031 for the UK, the big four EU markets and Japan; 2032 to 2033 for the US. Apotex got the first US tentative approval for a generic Ozempic in April 2026, and “tentative” there means roughly “approved, pending the calendar.”</p>
China is the odd one. Its compound patent expired on March 20, 2026, the same day as India’s. As of October, zero generic semaglutides had been approved in mainland China, because data protection there runs to approximately April 2027. Same molecule, same patent date, different lock.</p>

The pill is a separate contract</h2>
Anyway, everything above is about the injection. A formulation patent covering the SNAC absorption enhancer (the ingredient that lets semaglutide survive being swallowed, in a specific range) runs to 2031 in India, which blocks a generic version of the oral tablet even though the compound patent is gone. So India has, as of now, twenty-ish cheap injectable brands and no cheap pill, because of a patent on the thing that helps the drug get absorbed. Lol, but also: that is exactly what the patent says.</p>
Presumably the lawyers who drafted the oral formulation patent knew what the compound patent’s expiry date was. Different patents end on different days, and each one is read as literally as the court sentence above.</p>
If you are an Indian generic maker watching your domestic price fall toward ₹1,290 a month, you had better find a lot more countries where Novo Nordisk does not hold patent protection.</p>

Generic Victoza Is Already Here, and It Tells You What Comes Next

2026-11-01T00:00:00+00:00

On June 24, 2024, Teva Pharmaceuticals launched the first generic GLP-1 drug ever sold in the United States, and it was made by Novo Nordisk. Novo Nordisk is the company that makes the brand. Teva’s product was an “authorized generic” of Victoza (liraglutide injection 1.8 mg), launched under a 2019 patent settlement between the two companies, and one consumer guide put it plainly: “Both Teva’s authorized generic liraglutide and brand-name Victoza are manufactured by Novo Nordisk.” Same 18 mg/3 mL strength. Same pen. Different box.</p>

So the plain answer on generic victoza is that it exists, it has existed since mid-2024, and there are now several versions. After Teva came Hikma, whose traditional (non-authorized) generic liraglutide got FDA approval on December 23, 2024 and launched in early 2025, and then Meitheal, approved on April 2, 2025 and launched the following day. In August 2025 Teva also launched a generic of Saxenda, the higher-dose liraglutide for weight loss. The price did fall. It just did not fall the way people picture when they hear the word “generic,” and the reasons are a decent preview of what happens when the bigger GLP-1 drugs lose protection.</p>

Who launched generic Victoza, and in what order</h2>
The chain starts with patents. Novo held them, Teva wanted to sell liraglutide, and instead of litigating to the end they settled in 2019 and picked a date. Teva would go first, and as the first filer it got six months of exclusivity, after which DiaTribe reported that Sandoz and Viatris “could launch as soon as December 2024.” (Viatris is the company formerly known as Mylan, which is the sort of fact that matters only in pharma and in pub trivia.)</p>
You can picture the meeting. “Hey guys, instead of spending five years arguing about whether this patent is valid, what if we just agree on a Tuesday?” Everybody acting sensibly here, from where they sit: Novo would rather the first generic be one it manufactures, Teva would rather have a guaranteed launch than a coin flip in court, and both would rather skip the legal bills. It’s fine. It’s what settlements are for.</p>
The result is an arrangement where the generic is made in the brand’s plant, filled into the brand’s pen, launched on a date the brand signed off on, and sold by a company that used to be suing the brand. They share a molecule, a factory, a device and a calendar. The line between the two products is, let’s say, blurry. (The financial terms of the settlement are not in the sources here, so who earns what on each box is not settled.)</p>
Then the field widened. Hikma’s version was the first traditional generic liraglutide, meaning it was not a relabeled Novo product. Meitheal launched in 3-pen packs, with plans to expand. Sandoz and Viatris were reported to be developing versions as of June 2024. The sources also disagree, a little, about which of these was “first,” because the Victoza authorized generic, the Hikma generic and the Saxenda generic each got called the first something. Pharma firsts are sort of like airline loyalty tiers: there are a lot of them, and each one is technically true.</p>

What the price of generic liraglutide actually did</h2>
At launch, Teva priced its two-pack at $469.60. The brand was about $560. DiaTribe called that “only a 16-17% price reduction,” and the word “only” is doing honest work.</p>
I want to dwell on $469.60 for a second, because it is a wonderful number. It is not $470. Someone decided that the sixty cents mattered (and presumably there was a slide about it). And the three-pack was $704.40, which is exactly one and a half times $469.60, so every pen in either package cost precisely $234.80. This is a price set by people who know their unit economics to the penny and decided the penny should stay. Victoza had annual sales of $1.656 billion as of April 2024, so, look, the pennies add up.</p>
For contrast, a source on biosimilar and peptide pricing says US peptide generics “typically achieve only 15-40% price reductions versus reference products,” against 80-90% discounts typical for small-molecule generics, because the approval pathway is more expensive. Teva’s launch landed near the bottom of even that modest range.</p>
It did move after more sellers arrived. As of 2026, the average GoodRx price range for Teva’s generic liraglutide is $200 to $450 for a 2-pen package and $280 to $750 for a 3-pen package. The low end is well below launch. The top of the 3-pen range is above Teva’s launch price, which tells you that a “range” covers a lot of pharmacies doing a lot of different things, etc. What the typical patient paid at any given counter is not settled by these figures.</p>

Why the discount stayed small for so long</h2>
The point is that a 90% price drop needs a crowd. It needs a dozen manufacturers who each think undercutting the others is their best move. For six months, generic Victoza had one generic seller, and that seller’s product came off the brand’s own line. A one-company price war is a dumb idea, and nobody in this story had it.</p>
Here is an invented scenario, clearly made up, to show the logic. A pharmacy stocks brand Victoza and Teva’s authorized generic, both from the same Novo plant. A patient asks the pharmacist which is better. The pharmacist says they are identical, except one is $90 cheaper. Novo, seeing this, could launch a second authorized generic through another partner at $469.59. Then a third at $469.58. In theory the market fills with Novo-made liraglutide in a dozen boxes, each a cent cheaper, and the “competition” is a single factory racing itself down the price ladder one penny at a time. It never happened. But it explains why the real discount moved when Hikma and Meitheal showed up, not before.</p>
There is also a patent overhang. Liraglutide’s compound patent has expired, but a device patent on the injection button (US 9,265,893) runs to September 2032, and a method-of-use patent for cardiovascular conditions (US 9,968,659) runs to January 2037. One patent analysis describes this as “creating potential litigation risk for generic manufacturers despite the compound patent’s expiry.” If you are a generic company, that risk is a reason to enter carefully or not at all, and every company that stays out is one fewer seller pushing the price down. (The site’s article on the GLP-1 patent thicket covers how these stacks get built.)</p>

Did generic Victoza help with the shortage</h2>
The honest answer is that the sources here do not measure it. What can be said follows from the structure. An authorized generic made by Novo Nordisk adds a label, not a factory, so on its own it does not add supply; it moves existing pens into a cheaper box. Hikma and Meitheal are separate products, but how and where they are made is not described in these sources, so whether they meaningfully eased supply is not settled. For instance, a shortage caused by limited filling capacity would not be fixed by a new price tag, however carefully the sixty cents were chosen.</p>

What generic Victoza says about semaglutide</h2>
Compare India. When the core semaglutide patent expired there, over 40 generic brands launched on March 21, 2026, the day after expiry. Roughly ten days later, Novo cut Ozempic’s Indian price by 36% and Wegovy’s by 48%. That is what a crowd does. Liraglutide in the US got a negotiated date, a single first seller made by the brand, and a 16-17% discount, with larger cuts arriving only as independent sellers trickled in. (The country-by-country timelines for semaglutide are in the site’s other articles, and I won’t repeat them here.)</p>
So the American liraglutide story is less a race than a relay where the brand hands the baton to a partner it chose, then watches for whoever else shows up. I guess the main thing to watch with semaglutide in the US is not the expiry date by itself but how many strangers are allowed in on it, and when.</p>
The first American generic GLP-1 came out of Novo Nordisk’s own plant, in Novo Nordisk’s own pen, at $469.60. The next ones will come out of somebody else’s. That is when the price moves.</p>

Insurance and GLP-1s: Why Coverage Is a Bet on the Price Falling

2026-11-01T00:00:00+00:00

Ozempic had a 2024 list price of $959 for a 30-day supply in the United States, and almost nobody with health insurance is supposed to pay that, which is sort of the point of insurance and sort of the problem with it. If you typed in the Ozempic price with insurance, the honest answer is that there is no single number. It depends on whether your employer or insurer chose to cover the drug, for which conditions, at what copay, and after how much paperwork. The sources I have do not give a typical insured copay, and I am not going to invent one.</p>

What the sources do give is the shape of the decision. Without insurance, brand Ozempic or Wegovy runs $935 to $1,349 a month. Medicare’s negotiated price for Ozempic, Wegovy and Rybelsus is $274 per 30-day supply, effective January 1, 2027. Every health plan in America sits somewhere between those numbers, making a bet about how fast the price comes down. The price on your pharmacy receipt is the visible end of that bet.</p>

Why a health plan would hesitate to cover a drug that works</h2>
Start with a small, reasonable version. (This scenario is invented.) An employer runs a health plan for 100 people. One of them gets prescribed Ozempic, and the plan pays something near list price, call it roughly $11,500 a year. It’s fine. That is what a health plan is for: lots of people chip in so that the one person with an expensive problem does not pay for it alone.</p>
Now ten people are on it. Then the drug class picks up approvals for heart protection, kidney disease, fatty liver disease and sleep apnea (all of which happened before 2026), so the list of people with a good medical reason to take it gets longer. Now thirty people are on it. The line item is no longer a rounding error. It is a budget meeting.</p>
And here is where the employer’s finance person has a thought. The price of this drug is going to fall someday, because patents expire and generics arrive. So every month the plan pays $959 is, in a sense, a month of paying full price for being early. The rational response is to be less early. First the plan requires a doctor to fill out a form before it pays. Then it requires the patient to try something cheaper first. Then it covers the drug for diabetes but not for weight. Then it covers it with a copay big enough to be a conversation.</p>
Push it one more step and you get the logical endpoint: a plan that covers Ozempic in full, starting February 17, 2041, which is when U.S. Patent 11,318,191 (“GLP-1 compositions and uses thereof”) expires. That is a perfectly rational benefit. It is also perfectly useless. Nobody’s employer has written that exact rule, I assume, but the incentive points that way, and a lot of real coverage policy is somewhere along that road.</p>

Prior authorization is a queue with a form at the front</h2>
Prior authorization is the mechanism by which a plan says “yes, but prove it.” The prescriber documents that the patient meets the plan’s criteria, the plan reviews it, and only then does the plan pay. The specific criteria vary by plan, and the facts here do not settle what any particular plan requires, so I will not pretend they do.</p>
The cleanest way to think about it is a deli counter. Everyone is entitled to sliced turkey, but you have to take a number, and the number dispenser is in a different building, and it only accepts tickets signed by your doctor. Nobody is refused turkey. The line just moves slower than it would if turkey were cheap. When turkey gets cheap, the dispenser tends to disappear.</p>
I picture the meeting where this gets designed going something like: “Hey, what if we covered it, but made it slightly annoying?” “How annoying?” “About $959 a month annoying.” (I have never attended this meeting. I write a newsletter.) To be fair, the people in the meeting are doing their jobs, and their job is to keep premiums from going up for the other 70 employees who are not on the drug.</p>
The annoyance has spawned its own service industry. As of October 27, 2026, Walgreens added “virtual coverage navigation, Medicare GLP-1 Bridge support, and pharmacist follow-up calls for GLP-1 patients,” according to Pharmacy Times. “Pharmacist follow-up calls” is a very clinical phrase for what is, structurally, someone checking in after the first date to ask whether you’d like to keep seeing each other. When a pharmacy chain builds a department to help people get through their own insurance, the paperwork has become a product.</p>

What generic entry did to the math in India</h2>
If you are a health plan making a bet on price declines, India in 2026 is the dream scenario. Over 40 generic semaglutide brands launched on March 21, 2026, the day after the patent expired there. Before that, Ozempic cost about ₹8,800 to ₹11,175 a month (roughly $100 to $130). The generics came in at ₹1,800 to ₹4,200 a month (roughly $20 to $50). And then, as the Generic Guide puts it, “Novo Nordisk responded by cutting Ozempic 36% and Wegovy 48% within 10 days.”</p>
Ten days. That is less time than it takes most employers to schedule a benefits review. By October 8, 2026, the lowest stated monthly price for generic semaglutide in India was Rs 1,290 (roughly $15), for vials from Natco and Eris. That is a modest change.</p>
The point is that this is what the bet looks like when it pays off. Patent expires, dozens of competitors show up the next morning, the brand cuts its own price almost immediately, and anyone who waited gets the drug at a fraction of what the early buyers paid. It is a bit like The Price Is Right, if the contestants were actuaries and the showcase were a five-year spending forecast.</p>

Why the American version of that cliff is further away and shallower</h2>
The trouble with the bet in the United States is that the payoff date keeps receding. Semaglutide in America is covered by a stack of patents: three titled “Oral dosing of GLP-1 compounds” that run to May 2, 2034; three titled “GLP-1 compositions and uses thereof” that run to August 24, 2038; solid-composition patents running to February 1, 2039; and the one that runs to February 17, 2041. (The site has a whole article on the thicket, so I will leave the trees there.) Apotex received the first FDA tentative approval for a generic Ozempic on April 10, 2026. “Tentative” is doing real work in that sentence, and the facts here do not say when it becomes a launch.</p>
Then there is the question of how far the price falls once a generic does arrive. America has a test case. Teva launched an authorized generic of Victoza, an older GLP-1, on June 24, 2024, priced at $469.60 for a two-pack against about $560 for the brand. DiaTribe called that “only a 16-17% price reduction.” Prost Biotech says peptide generics in the U.S. typically get 15 to 40% discounts, versus 80 to 90% for small-molecule generics, “due to the more expensive biosimilar approval pathway.” So an American health plan waiting for semaglutide to go generic may be waiting a decade for a discount smaller than the one India got in ten days.</p>
And while it waits, the market moves. Eli Lilly overtook Novo Nordisk as the GLP-1 market leader by 2026, with tirzepatide protected by a U.S. compound patent until May 13, 2036. So the plan’s bet on semaglutide prices falling is partly a bet on a drug that may not be the one its members are prescribed. That is a little dumb, but it is the system’s dumb, not anyone’s in particular.</p>

Medicare’s $274 is the closest thing Americans have to a generic</h2>
Semaglutide was included in the second round of Medicare price negotiations under the Inflation Reduction Act, and the result is $274 per 30-day supply starting January 1, 2027. Against the 2024 list price of $959, that is about 71% off. Nobody had to wait for a patent to expire. The government just asked, with leverage.</p>
This matters for everyone else because it changes the reference point. A commercial insurer negotiating with a manufacturer now knows that a large buyer can get the same molecule for $274. Whether that number pulls commercial prices down, and by how much, is not settled by anything I have. I guess it would be strange if it pulled them up.</p>
Look, the whole arrangement is coherent once you see it as a bet: plans restrict coverage now because the drug is expensive now, and they expect it to be cheaper later, through patents expiring, generics arriving, negotiation, or a brand cutting its own price to hold its ground, etc. The restrictions are the cost of waiting. Patients bear part of that cost in forms and copays. Pharmacies bear part of it in follow-up calls. Employers bear the rest in budget meetings.</p>
Which means that, as of January 1, 2027, the cheapest coverage strategy for an American employer is to wait for its employees to turn 65.</p>

The GLP-1 Patent Thicket: Why One Drug Has Dozens of Patents

2026-11-01T00:00:00+00:00

Here is a small fact about Ozempic: depending on who is counting, it is protected by 21 patents, or 19, or 39. The FDA’s Orange Book, which is the official list of patents attached to an approved drug, lists 21 for Ozempic, two of which cover the drug substance itself. Private patent trackers count about 39 U.S. drug patents for Ozempic, of which roughly 19 are still active. Two are about the molecule. The rest are about other stuff.</p>

So if you typed “ozempic patent” into a search engine hoping for one expiry date, the plain answer is that there isn’t one. The core U.S. compound patent, US 8,129,343, runs to December 5, 2031. Novo Nordisk, in its 2025 Form 20-F, gives the U.S. compound expiry for Ozempic, Rybelsus and Wegovy as 2032. Secondary patents run to 2038, and one runs to 2041. The date a cheaper generic actually reaches American pharmacies is set by litigation settlements whose terms are confidential, and those settlements, according to Generic Guide, “point to generic entry around 2032.” The patent is not a single thing. It is a thicket.</p>

How many patents a GLP-1 drug normally has</h2>
Ozempic is not unusual here. A JAMA study of GLP-1 receptor agonists found a median of 19.5 patents per product, with 54% of those patents covering delivery devices rather than active ingredients, and a median total expected protection of 18.3 years after FDA approval. Rybelsus, the pill version of semaglutide, has 15 U.S. drug patents filed between 2019 and 2026, 14 of them active. By the standards of its class, Ozempic’s 21 listed patents is sort of average.</p>
The weird part is the ratio. More than half the patents on a typical GLP-1 drug are about the pen. The drug is the reason anyone buys the product, and most of the paperwork is about the plastic (which is, in fairness, the part you can hold).</p>

The Ozempic patent that matters, and when it ends</h2>
The patent everyone means is the compound patent, the one that claims the molecule. It expires in 2026. Actually, no: it was originally due to expire in 2026, and then Novo Nordisk received a Patent Term Adjustment of 1,114 days and a Patent Term Extension of 1,040 days on its U.S. semaglutide drug substance patents (the first compensates for time spent at the patent office, the second for time spent getting the drug approved). That pushes the term to December 5, 2031, and Novo itself reports 2032 as the effective date. So the core patent ends about five years after it would have, under rules designed so that it would.</p>
There is a second core patent, US 8,536,122, titled “Acylated GLP-1 compounds,” which protects Ozempic, Wegovy and Rybelsus and appears in four separate drug applications. Its principal commercial claim, claim 9, identifies Aib8,22, Arg34-GLP-1(7-37), which is the peptide backbone of semaglutide. That is the actual invention, written in a notation that only a few hundred people can read comfortably (and they all bill hourly).</p>

Why a pen gets patents too</h2>
Then come the secondary patents, which is where the dates spread out. Three patents titled “GLP-1 compositions and uses thereof” cover Ozempic, Wegovy and Wegovy HD and expire August 24, 2038. A fourth with the same title, US 11,318,191, runs to February 17, 2041. “Semaglutide in medical therapy” covers Ozempic to October 10, 2038. “Semaglutide in cardiovascular conditions” runs to April 28, 2037. Trackers say Ozempic’s patents also include the injection pen, with expiries spread across 2031, 2034 and 2037.</p>
And then, for instance, there are patents titled “Oral dosing of GLP-1 compounds,” expiring May 2, 2034, which trackers list as covering Ozempic and Rybelsus. There are also two patents on “solid compositions” of a GLP-1 agonist with an absorption enhancer called SNAC, expiring February 1, 2039, listed as covering Ozempic and Wegovy. Ozempic is a liquid in a pen. The facts available here do not settle why an oral-dosing patent sits under an injection (it may be how the trackers group patent families, or whatever), but it does give you a sense of how wide the fence is drawn.</p>
The pen patents make sense from inside a drug company. An improvement to a dosing button is a real engineering change, and filing on it is cheap relative to what the drug earns. Here is an invented conversation, for illustration only: “We moved the dose counter two millimeters.” “File.” “It’s two millimeters.” “File twice.”</p>
This matters because a device patent can outlive a molecule patent. Victoza, the older Novo drug liraglutide, has a device patent on its injection button running to September 2032 and a cardiovascular method-of-use patent running to January 2037, even though its compound patent is gone. A generic maker can copy the molecule freely and still get sued over the button.</p>

Litigation, settlements, and the date nobody publishes</h2>
How does a generic actually get onto the American market, then? Not by waiting for every one of the 21 patents to lapse. A generic company files with the FDA, challenges the patents it thinks are invalid or not infringed, and the brand sues. Then, usually, everybody settles.</p>
Novo Nordisk settled its U.S. Ozempic patent litigation with Alvogen, Rio Biopharmaceuticals, Sun Pharma, Dr. Reddy’s, Mylan, Zydus and Apotex. All of the settlement terms are confidential. Apotex has already received the first FDA tentative approval for a generic Ozempic, which, as the law firm Pearce IP puts it, means the product “meets all statutory and regulatory requirements for approval but cannot be marketed in the US because of patents or exclusivities.” The generic is finished. It is waiting on a contract.</p>
The Victoza precedent shows how this plays out. Teva launched the first U.S. generic GLP-1, an authorized generic of Victoza, on June 24, 2024, under a settlement signed with Novo in 2019. The entry date was decided five years before it happened, privately, and it was not the date printed on any patent.</p>
Everyone in this is behaving sensibly from where they sit. Novo is protecting the revenue that funds its next drug. The generic makers would rather have a certain launch date than a coin flip in court over 19 patents. The FDA lists what it is given (which is a job description, not a complaint). The fight is now repeating with Eli Lilly, which overtook Novo as the GLP-1 market leader by 2026 and sued 14 generic companies, including Sandoz and Dr. Reddy’s, in August 2026 over challenges to tirzepatide, whose compound patent runs to May 13, 2036.</p>

Three ways to read the thicket</h2>
There are, roughly, three ways to read all this.</p>
The first is that the patents are just inventions. Semaglutide works (the drug class has helped patients lose up to 20% of their body weight), and the pen, the formulations and the cardiovascular uses each took real work. On this reading, 21 patents means 21 things somebody figured out, and the 2038 expiries are simply what happens when you keep improving a product. It must be tiring to keep inventing useful refinements at exactly the moment the earlier ones start to expire, and presumably the timing is a coincidence.</p>
The second is that the patents are bargaining chips. A patent that would probably lose in court is still worth something, because litigating it is slow and uncertain, and uncertainty is what a settlement buys. On this reading, the secondary patents aren’t really meant to last until 2038. They are meant to make 2032 feel like a good deal. Industry analysts describe the U.S. semaglutide market as protected by a thicket “through 2033,” which is later than the molecule and much earlier than the last patent, and is roughly what you would expect if the patents were mostly there to be traded.</p>
The third reading is the least comfortable. The date that matters to patients and insurers, the day the price can actually fall, is not public law at all. It is a term in seven confidential contracts. You can read every patent, count them however you like, and still not know when generic Ozempic arrives in the U.S., because the answer was negotiated by the parties and the people paying for the drug were not among them. I don’t know what the settled dates are. Neither, officially, does anyone outside those rooms. Anyway, the patents are public and the date isn’t.</p>
So Ozempic has 21 patents, or 19, or 39, and the one number a patient cares about is the one nobody gets to count. The only place where the count went to zero early was Canada, where the main patent lapsed in 2019 because Novo did not pay a maintenance fee of CAD $250, roughly $180.</p>

Is Generic Semaglutide the Same as Ozempic?

2026-11-01T00:00:00+00:00

One thing that happens when a drug patent ends is that the word “same” suddenly needs a regulator. For years there was one semaglutide for diabetes, it was called Ozempic, and Novo Nordisk made it. Now Health Canada has approved copies from Dr. Reddy’s and Apotex, India has dozens of them, and people would like to know whether the copy is the thing.</p>

The plain answer is yes, in the specific sense regulators mean it. Generic semaglutide contains the same active ingredient as Ozempic, at the same dose, for the same disease, and it is allowed to differ in everything around that (the name, the inactive ingredients, the look, the packaging, sometimes the injection device). As of September 2026 it was on sale in India, Canada, Brazil, South Africa and Saudi Arabia. It was not on sale in the US, where Apotex holds only an FDA “Tentative Approval” from April 10, 2026, and the compound patent is extended to December 5, 2031 (Novo Nordisk itself reports 2032).</p>

The dumb version says it is the same molecule, so it is the same</h2>
Here is the dumb version. Ozempic is semaglutide. The generic is semaglutide. So the generic is Ozempic. Done.</p>
I feel like this is basically correct, which is an awkward thing to admit at the top of an article whose whole job is nuance. The molecule is the medicine. When the compound patent ran out in India on March 20, 2026, more than 40 brands launched the next day, which is what happens when the only thing standing between a market and a molecule is a date.</p>
The dumb version even has some official backing in the US. According to IQVIA, the FDA “treats any peptide chains of under 40 amino acid residues as a generic drug.” Semaglutide has 31 amino acids, so it goes down the ordinary generic road, the Abbreviated New Drug Application that Apotex used. (My entire qualification for discussing peptide chemistry is the ability to count to 40, which turns out to be the relevant skill here.) Tirzepatide has 39. Close call.</p>

The sophisticated version asks what a regulator means by “same”</h2>
The sophisticated version starts with a definition. The European Medicines Agency says a generic “contains the same active substance(s) as the reference medicine, is used at the same dose(s) to treat the same disease(s), but may differ in inactive ingredients, name, appearance, and packaging.”</p>
That last clause is the interesting part. “May differ in inactive ingredients, name, appearance, and packaging.” Translated: the drug is identical and everything you can see is allowed to be different.</p>
So “same” to a regulator is not one test but several stacked up. Same active substance. Same dose. Same disease. Health Canada’s description of the Dr. Reddy’s product reads like it was traced over Ozempic’s job description: “indicated for once-weekly treatment of adult patients with type 2 diabetes.” Apotex’s May 1 approval carries the same wording. The generic is not supposed to be a better Ozempic or a different Ozempic. It is supposed to be the Spider-Man pointing at the other Spider-Man.</p>
On the other hand, a generic does not have to copy every job the brand ever had. On June 29, 2026, Health Canada authorized Apotex’s Sevmia, the first generic semaglutide for weight loss, for patients 12 and over, “as a supplement to a reduced-calorie diet and increased physical activity for chronic weight management.” Same molecule, different job, different name. (Whether that makes it a generic Wegovy is a naming fight another article on this site handles.)</p>

Proving a peptide copy is the same takes longer than saying it</h2>
Here is the catch with “same active substance.” You cannot just declare it. You have to show that your semaglutide, made your way, gets into the body and behaves there the way Novo Nordisk’s does, closely enough that the gap does not matter. In plain words: make your own, then prove the body cannot tell. The official name is bioequivalence.</p>
For small-molecule pills this is the well-worn part of the process. For an injected peptide, according to industry commentary on the Apotex approval, it “carries a higher analytical burden.” In practice that means more lab work before anyone gets to say “same.” Somewhere a chemist is saying “hey guys, the data matches, can we please be done,” and somewhere a reviewer is saying “one more batch” (I am inventing both of them, though not the dynamic).</p>
China shows how long the long road can be. Its compound patent expired on March 20, 2026, the same day as India’s. Hangzhou Jiuyuan Gene Engineering said back in April 2024 that its version had achieved “comparable efficacy and safety to Ozempic,” and Jiuyuan Genetic Biopharmaceutical’s application for a Wegovy copy was accepted for review in February 2026. As of October 2026, China had approved zero generic semaglutides, with data exclusivity there running to roughly April 2027. The molecule was free. The paperwork was not.</p>

The pen is where “same” gets expensive</h2>
Between us, the molecule is the boring part. The interesting part is the plastic thing you inject it with.</p>
Pen device patents for semaglutide in Canada are reported to run to at least 2033, years past the compound. So the drug can go generic while the delivery hardware stays protected, and the facts available here do not settle exactly how each Canadian generic handles that. In India, where the market answered the question directly, Natco and Eris charged about three times as much for a semaglutide autoinjector pen as for a vial of the same molecule. Same drug. Triple price.</p>
Let me push this, in an invented scenario. Suppose a generic maker has to avoid every claim in a pen patent. It removes the dial, then the click, then the little window, then the cap shape, until it ships a device that works by turning a brass knob seven times while held at a precise angle, and a regulator reviews it and finds it delivers “the same dose(s).” The patent lawyers are delighted. The regulator is satisfied. It is the same drug. It is also, I mean, a brass knob.</p>
For contrast, Teva’s authorized generic liraglutide, the Victoza equivalent, comes in the same 18 mg/3 mL strength and uses the same pen device as the brand-name product. That is one way to make “same” easy.</p>

What patients notice about generic semaglutide, and why both roads end in the same place</h2>
What does a patient actually see? Mostly the things the EMA said could differ: a different name, a different box, maybe a different device, and a different price. In India, Ozempic had cost about ₹8,800 to ₹11,175 a month (roughly $100 to $130); generics came in at ₹1,800 to ₹4,200 (roughly $20 to $50). Novo Nordisk cut Ozempic by 36% and Wegovy by 48% within about 10 days, and generics still took 50% of semaglutide sales by value in April 2026. India’s regulator, CDSCO, said on March 24 that it had inspected 49 entities and issued notices related to generic promotion, which suggests some of the marketing was creative.</p>
In Canada, approval is not the same as access. Provincial formulary listings, not the Health Canada authorization itself, decide what people can actually get and how hard prices compete. That matters in a country where Ozempic was the best-selling drug of 2025, at $2.9 billion in sales and more than three times the runner-up, with over one million Canadians on it. Canada got there first among G7 countries because a Novo Nordisk patent lapsed in 2019 over a CAD $250 maintenance fee (roughly $180, lol), a story another article tells in more loving detail.</p>
So here is where the two versions end up. The dumb version said: same molecule, same drug. The sophisticated version said: same active substance, same dose, same disease, demonstrated bioequivalence, with the name, appearance, packaging and possibly the device free to vary. I suppose that is the same answer, reached by a longer road and a lot more batch testing. It is the same drug in a different box, and sometimes the box is spelled differently.</p>
The Health Canada press release calls Apotex’s weight-loss semaglutide “Sevmia.” The CNW Group press release for the same product calls it “Svemia.”</p>

Medicare Picked Semaglutide for Price Negotiation. Here Is What Happens Next.

2026-11-01T00:00:00+00:00

On January 1, 2027, Medicare starts paying $274 for a 30-day supply of Ozempic. That is not the $959 list price from 2024. It is not a generic price either, because in the United States there is no generic semaglutide on the shelf. It is a number the federal government and Novo Nordisk reached by negotiating, under the Inflation Reduction Act, over a drug that Novo still holds patents on for years.</p>

So the medicare ozempic price, the thing people actually type into search boxes, is $274 per 30-day supply starting in 2027. The same price covers Wegovy and Rybelsus, which are also semaglutide. The patent watchdog group I-MAK notes that the three drugs “were included in the second round of Medicare drug price negotiations under the Inflation Reduction Act.” The facts do not settle how that price will interact with the generics lined up for the early 2030s. That is the interesting part.</p>

What Medicare will pay for Ozempic starting in 2027</h2>
DrugPatentWatch says the negotiated figure “represents a 71% reduction from the 2024 list price of $959.” I write about money, which means my main professional skill is dividing one number by another and then acting surprised. So let me do that. $274 divided by $959 is about 0.286. Medicare will pay a bit more than a quarter of the sticker price. For a patented drug. For a drug family that, per IQVIA, did $26 billion in combined Ozempic and Wegovy sales in 2024 while growing about 40% a year.</p>
And look at the number itself. It is not $275, which is the number a person would pick. It is not $250, which is the number a person would ask for. It is $274, the number you get when two large institutions with spreadsheets argue for a long time and nobody wants to round. It works out to about $9.13 a day (I checked twice). It has the specific, slightly tired quality of a price that both sides can explain to their bosses.</p>

Why bother negotiating if generics are coming anyway</h2>
Here is the sensible objection. Drugs go generic. Patents expire, competitors pile in, prices fall, and that is the system working as designed. Semaglutide’s US compound patent runs to around 2031 or 2032. Why have the government haggle over a drug that the normal process will cheapen on its own in five years or so?</p>
This is a fair point, and the evidence from elsewhere sort of supports it. In India, more than 40 generic semaglutide brands launched on March 21, 2026, the day after patent expiry. About ten days later Novo cut the Indian price of Ozempic by 36% and Wegovy by 48%. That is what generic entry is supposed to do, and it did it fast. (The India story has its own article on this site; the short version is “a lot of companies, all at once.”)</p>
But the mechanism in the US is stranger than the objection assumes. For this particular kind of drug, in this particular country, the negotiation produced a discount that is bigger than what generic entry has usually produced. The point is that waiting for generics might not have gotten Medicare to $274 at all.</p>

When generics can actually show up in the US</h2>
The compound patent, US 8,129,343, was extended through patent term restoration to December 5, 2031. Novo Nordisk’s 2025 Form 20-F gives 2032 as the US compound expiry for Ozempic, Rybelsus and Wegovy. Then there are the secondary patents (there are always secondary patents). One titled “Semaglutide in medical therapy” covers Ozempic and runs to October 10, 2038. Another on cardiovascular conditions runs to April 28, 2037. Others cover the pen, oral dosing, etc.</p>
The generic makers are already queued up. On April 10, 2026, Apotex got the first FDA tentative approval for a generic Ozempic. “Tentative” is the operative word, since the patents still stand in the way. Under the Hatch-Waxman Act, a brand company can trigger an automatic 30-month stay of generic approval by listing patents in the FDA’s Orange Book (a list of things a company would like protected, and companies differ in how much they feel needs protecting). The country-by-country dates live in another article. For Medicare, what matters is that the earliest plausible generic window sits years after the $274 price takes effect.</p>

What generic entry does to the price of a drug like this</h2>
India’s numbers are dramatic, but India started from a different place. In the US, the track record for peptide drugs is more modest. Prost Biotech writes that US generic peptide drugs typically get only 15 to 40% price reductions, compared with 80 to 90% for small-molecule generics, “due to the more expensive biosimilar approval pathway.” Making a copy of a complicated molecule is expensive, and the copier wants to be paid for the trouble.</p>
The nearest example is semaglutide’s older sibling. When Teva launched generic Victoza in the US, it was priced at $469.60 for a two-pack against roughly $560 for the brand. That is a 16 to 17% discount, with more competition expected later. It’s fine. It is just not 71%.</p>

How a negotiated price and a generic price collide</h2>
Here is a hypothetical, entirely made up, using Victoza-style math. It is 2032, and a generic maker launches semaglutide at 16% off the old $959 list price. That comes to about $805. At the full 40% from the top of the typical range, it is about $575. Both numbers are well above $274.</p>
Picture the launch meeting. “Hey guys, great news, we’re coming in at a 16% discount.” “A discount to what?” “To the price nobody in Medicare pays.” Push it further. The generic salespeople pitch Medicare on an identical molecule at three times the price, Medicare politely declines, and the generic maker cuts again. Eventually someone launches “generic semaglutide, now only slightly more expensive than the brand,” which is a dumb product to sell. That is about how it feels when the outlet store marks things down from the original tag while the main store is already running a bigger sale.</p>
The real world probably won’t go like that, and the facts here do not say how it will go. They do not settle whether the negotiated price holds once generics arrive, or what US generic makers will actually charge. The point of the hypothetical is just that the usual order (brand price high, generic price low) can flip when the government negotiates the brand down first.</p>
And everyone involved is behaving reasonably. Medicare is a huge buyer and was never going to wait until 2032 for relief. Novo, I guess, would rather take a negotiated price it can plan around than an uncertain one. Generic makers face an expensive approval pathway and need to price against something, so they price against the brand.</p>

What the savings estimates say</h2>
A study re-estimating Medicare spending on semaglutide for 2026 through 2035 puts base-case savings at $463 million under the negotiated price. Combine Most Favored Nation pricing with generic entry assumptions and the figure rises to $2.63 billion (which is what happens when a model gets two wishes instead of one). Set against $26 billion in sales in a single year, $463 million over ten years is not a huge number. For instance, it averages about $46 million a year.</p>
Why a 71% headline cut produces savings that small is not something these facts explain. The study’s assumptions do that work, and I don’t have them. What the range does show is that the people modeling it think generic timing still matters a great deal, on top of the negotiation, not instead of it.</p>
So back to the $274. In 2027 Medicare starts paying it for a brand-name drug. Somewhere around 2032 generics may arrive, priced off a list price that Medicare stopped paying years earlier. Medicare’s first cheap semaglutide will be Novo’s own.</p>

How Ozempic Coupons and Savings Cards Actually Work

2026-11-01T00:00:00+00:00

The way a coupon works is that a store wants you to buy something, so it hands you a slip of paper that makes the thing cheaper, and the store eats the difference where everyone can see it on the receipt. An ozempic coupon (usually called a savings card or copay card) is a stranger object. It does not make Ozempic cheaper, exactly. It makes the part of the price that you personally pay at the pharmacy counter cheaper, with the manufacturer, Novo Nordisk, covering some of your share, while your insurer still pays its share of a drug that had a 2024 list price of $959 per 30-day supply.</p>

Who gets one: generally, people with commercial insurance that covers the drug. Who does not: people on Medicare and other government plans, who are excluded from manufacturer copay cards. There is also a catch for people who do qualify. Some insurers run what are called accumulator programs, which let the coupon money pay for the drug but do not count that money toward the patient’s deductible. The specific dollar caps and fine print on any particular card are not in the sources behind this article, and they change, so I will not pretend to know them. What follows is the mechanism, which is weirder than the dollar amounts anyway.</p>

How a copay card is different from a grocery coupon</h2>
Start with the small, reasonable version. A grocery coupon takes $1 off cereal. The price falls, you pay less, the store and the cereal company sort out who absorbs it. Everyone can see what happened.</p>
A drug copay card has three parties instead of two. The pharmacy charges the insurer, the insurer pays most of it, and the patient owes a slice (a copay, or coinsurance, or the whole thing if they have not met their deductible yet). The card attacks only that slice. The insurer’s share is untouched. So the manufacturer is not lowering its price. It is lowering the visibility of its price to the one person in the transaction who was going to feel it.</p>
This is sort of brilliant, if you are the manufacturer. A patient who sees a big bill might ask the doctor about something cheaper. A patient who sees a small bill does not.</p>

The escalation, one reasonable step at a time</h2>
Here is a made-up example, clearly marked as made up, with invented numbers. A patient has a $1,000 deductible. Without a card, the first $1,000 of drug costs in the year come out of their pocket, and then the insurer starts paying more. With a card, the manufacturer pays that $1,000 on the patient’s behalf. The deductible gets met. The insurer starts paying. Fine.</p>
Step two. The insurer notices that the deductible, which it designed specifically so that patients would feel some cost and choose cheaper drugs, has been paid by the company selling the expensive drug (which is not quite the incentive the actuaries drew on the whiteboard). From where the insurer sits, this is a little like a casino lending you chips and calling it your own money.</p>
Step three. So the insurer stops counting the coupon money toward the deductible. The card still pays for the prescriptions. But on the insurer’s books, the patient has paid nothing. In our made-up example, the card runs out at its annual limit in, let’s say, August, and the patient discovers that their deductible is still $1,000, untouched, and now theirs.</p>
Step four, pushed to the absurd end. The manufacturer raises the card limit to cover the whole year. The insurer raises the deductible on specialty drugs to match the card limit, since it is not counting that money anyway. The manufacturer raises the card again. Eventually every dollar of the deductible flows from Novo Nordisk to the insurer, through the patient’s pharmacy account, and the patient is sort of a pipe. It is splitting the check at dinner, where one friend pays, and the restaurant decides the payment happened to someone else.</p>
I write about finance for a living, which mostly means I take ordinary payments and describe them as though they were elaborate derivatives. This one actually is.</p>

How accumulator programs take the coupon back</h2>
The real world is most of the way down that road. Accumulator programs are step three, and they exist. The precise terms vary by plan and are not settled by the sources here, so I can describe the shape but not your plan’s version of it.</p>
The sympathy goes around the table, honestly. The manufacturer wants patients to stay on a drug it believes in, and it would rather pay a patient’s copay than lose them at the counter. The insurer wants its cost-sharing design to work, because otherwise the deductible is a decoration. The pharmacist is just processing two claims for one box (which is, to be fair, a lot of paperwork for one box). The patient wants the medicine and did not design any of this.</p>
You can imagine the meeting at a benefits consultancy. “So the card is basically free money,” someone says, “we just don’t count it.” And nobody in the room is wrong on their own terms.</p>

Why Medicare patients can’t use the card</h2>
Medicare beneficiaries are excluded from manufacturer copay cards. The usual explanation is a federal concern about drug companies paying to steer government-funded purchases, and I am going to gesture at that rather than litigate it, because the details are not in my sources.</p>
So Medicare patients get no coupon. Actually, that is not quite right. They get no coupon from Novo Nordisk, and instead they are getting something that looks a lot like a coupon from Medicare itself. Semaglutide was picked for price negotiation, and DrugPatentWatch reports that “the Medicare negotiated price for Ozempic, Wegovy, and Rybelsus is $274 per 30-day supply, effective January 1, 2027.” Before that kicks in, Disclosed Labs describes a program called the Medicare GLP-1 Bridge, which “provides a $50 copay” for Part D beneficiaries, running from July 1, 2026 to December 31, 2027.</p>
Who exactly qualifies for the Bridge, and how it interacts with each Part D plan’s design, is not settled by the facts I have. But notice the structure. The government said a drug company cannot pay down a Medicare patient’s copay. Then the government built a program that pays down a Medicare patient’s copay. Presumably the difference is who is holding the pen.</p>

What generic entry does to the coupon</h2>
A copay card is a tool for a world where the list price stays high and the brand has no competition. It lets the manufacturer keep the sticker at $959 while softening the one part of it a patient sees. That world has an end date, more or less.</p>
In the US, the main semaglutide compound patent is extended to December 5, 2031, exactly 14 years after the FDA approved Ozempic, and Novo Nordisk reports 2032 as the effective compound expiry. Apotex received the first FDA tentative approval for a generic Ozempic on April 10, 2026. But Novo settled its US Ozempic patent litigation with seven generic makers, including Apotex, and all the settlement terms are confidential. So the actual US launch date for generics is not settled, and trackers count roughly 19 active Ozempic patents, some running to 2041. The site’s other articles go through those dates in detail.</p>
What happens at the cliff is less mysterious. In India, over 40 generic semaglutide brands launched on March 21, 2026, the day after patent expiry, and about ten days later Novo cut the Ozempic price there by 36% and Wegovy by 48%. Nobody needed a coupon. The price just moved, for everyone, visibly, like a grocery store price.</p>
What happens to US copay cards and accumulator programs when that day comes here, I don’t know. I would rather not think too hard about what the various benefits teams have planned for the 2032 plan year.</p>

Back at the counter</h2>
So picture the grocery coupon again: $1 off cereal, the store eats it, everyone sees it. The Ozempic version is the same slip of paper, except it is aimed at one shopper in the line, it counts only if the owner of the register says so, and the shoppers on Medicare are not allowed to use it at all, or at least not this one, or whatever.</p>
The cheapest Ozempic coupon in America right now is the $50 one, and it is issued by the government to the only people who are forbidden to use coupons.</p>

The Ozempic Price Without Insurance, Explained Without Panic

2026-11-01T00:00:00+00:00

Novo Nordisk sells one molecule at a surprising number of prices, and which one you pay depends mostly on which door you walk through. In 2024 the US list price of Ozempic was $959 for a 30-day supply, and a 2026 guide to compounding law put the ozempic price without insurance (brand-name Ozempic or Wegovy, bought at a regular pharmacy) at “$935 to $1,349 per month.” That is the number most people find when they search. It is a real number. It is just not the only one.</p>

The other door is Novo’s own pharmacy. As of October 21, 2026, the self-pay price for Wegovy through NovoCare Pharmacy started at $199 a month for the pen and $149 a month for the pill. Wegovy and Ozempic are both semaglutide (the same US patents cover both), but they are separate products with separate labels, and the facts here do not settle what a comparable direct cash price for Ozempic itself is. So the plain answer is roughly a thousand dollars a month at the counter, around a fifth of that for the sister product bought directly from the manufacturer, and an Ozempic-specific direct number that is not pinned down here.</p>

What the Ozempic price without insurance is made of</h2>
The arrangement looks a lot like a hotel. There is a rate printed on a card on the back of the room door, and there is the rate the hotel’s own website will sell you that same room for tonight. The door rate is real in the sense that it is printed. The website rate is real in the sense that people book it.</p>
Why would a company keep both? I assume because the list price is the starting point for a lot of other arrangements (insurers, pharmacy benefit managers, government programs, etc.), and cutting it moves all of those at once. A separate cash channel lets you charge uninsured people less without touching the number everything else is built on. It’s fine. It is how a great many things are priced. It just means that “what does Ozempic cost” turns into a Price Is Right round where several different guesses are correct and the host does not say which one counts.</p>

The dumb version: generics arrive and the price falls</h2>
The simple story of drug prices goes like this. A company gets a patent, the patent runs out, other companies make copies, the copies are cheaper, and the original gets cheaper too. I call this the dumb version with affection, because in India in 2026 it is more or less exactly what happened.</p>
Novo’s core semaglutide patent was filed on March 20, 2006, which gave it a 20-year term ending March 20, 2026 in countries that did not extend it. India was one of those. On March 21, the day after expiry, over 40 generic semaglutide brands launched. Sun Pharma’s launch price per weekly injection worked out (by one outlet’s calculation) to roughly 61% to 66% below Novo’s branded monthly price band. Within about ten days Novo had cut the price of Ozempic in India by 36% and the starting dose of Wegovy by 48%, the latter on April 1.</p>
That is a company making a modest adjustment to its plans. Forty competitors showed up overnight and it rethought things in a week and a half. Nobody had to order it to.</p>
Some countries do not even leave the size of the discount up to the market. Under Brazilian law, a generic has to be sold at least 35% below the reference product’s price, and when several generic makers enter, the cuts there typically reach 50% to 80% below the originator. That is the dumb version written into statute, which is its own kind of compliment (the legislature trusted the simple story enough to make it mandatory).</p>
The broader data says the same thing with more decimals. FDA figures show generic prices about 39% below the brand with one generic maker and more than 95% below with six or more. Look, forty is more than six.</p>

The sophisticated version: no generics, and the price falls anyway</h2>
The United States did not get the dumb version. Here the compound patent, US 8,129,343, was extended through patent term restoration to December 5, 2031, which is exactly 14 years after the FDA approved Ozempic on December 5, 2017. Novo itself lists 2032 as the effective US compound expiry, and secondary patents run to 2038. Apotex got the first FDA tentative approval for a generic Ozempic on April 10, 2026, which is an approval with the word “tentative” doing a lot of work in it.</p>
Novo also settled its US Ozempic patent fights with Alvogen, Rio Biopharmaceuticals, Sun Pharma, Dr. Reddy’s, Mylan, Zydus and Apotex, and all of the settlement terms are confidential. (So when any of them may actually launch is not settled, at least not publicly.) It must be a real strain for seven generic companies to sit on information like that, and I am sure they would announce their launch dates tomorrow if only the paperwork allowed it.</p>
So: no generic semaglutide for sale in America. And yet the cash price came down anyway, by a longer road. Compounding pharmacies sold injectable semaglutide for an average of $230 a month, more than half off the brand (that is a whole other story, told elsewhere on this site and not here). Then semaglutide was picked for the second round of Medicare price negotiation under the Inflation Reduction Act, and the negotiated price for Ozempic, Wegovy and Rybelsus is $274 per 30-day supply starting January 1, 2027. DrugPatentWatch notes that this “represents a 71% reduction from the 2024 list price of $959.” And then there is NovoCare, selling the Wegovy pen from $199.</p>
I picture the pricing meeting going something like this (I am inventing it): “Great news, we are cutting the price.” “Which price?” “Not that one.” The point is that India got a big cut because forty rivals walked in the front door, and the US got a cut of a similar size because compounders, the federal government and the company’s own cash program all came in through side doors. Different road. Same neighborhood.</p>

Why the cash price can still move up</h2>
To be fair, cash prices are not a one-way street. Eli Lilly raised the UK price of Mounjaro, its rival drug, in about September 2025, and Pharmaceutical Technology reported the stated reason as a move to “better reflect market conditions.” Market conditions, in that sentence, were being reflected upward.</p>
Nor does generic entry in the US guarantee the Indian-style plunge. Peptide copies here have tended to come in only 15% to 40% below the reference product, against the 80% to 90% discounts typical for simple pill generics, because the approval path is more expensive. The nearest test case is liraglutide, the older GLP-1 sold as Victoza. When Teva launched its generic, DiaTribe described the launch price as “only a 16-17% price reduction” from the brand, with more competitors expected to follow. In 2026 the average GoodRx range for Teva’s generic liraglutide was $200 to $450 for a two-pen package. That is cheaper. It is not cheap.</p>

What happens to the cash market from here</h2>
The calendar is fairly crowded. Medicare’s $274 price takes effect in January 2027. China’s compound patent also expired on March 20, 2026, but data protection there runs to about April 2027, and at least 17 Chinese manufacturers are in late trials or awaiting approval. US generics are tied to a 2031 or 2032 patent date and to settlement terms nobody will discuss. I guess that leaves the American cash price to be set the way it has been set lately, by competition that does not technically exist yet and by a manufacturer pricing against it in advance.</p>
Which produces one odd result. Come January, the price the federal government spent a statutory negotiation winning for Wegovy will be $75 more than the starting price Novo already charges people with no insurance at all.</p>

Why Ozempic Costs What It Costs

2026-11-01T00:00:00+00:00

Here is a small fact about Ozempic: in 2024, according to DrugPatentWatch, “the 2024 list price of Ozempic was $959 per 30-day supply in the United States.” That is the number most people are looking for when they type “ozempic price” into a search bar, and it is real in the sense that it is written down. It is less real in the sense that it is not obviously what anyone in particular pays.</p>

The plain answer goes like this. The sticker was $959 a month. Brand-name Ozempic or Wegovy without insurance is quoted at $935 to $1,349 a month. Medicare’s negotiated price, starting January 1, 2027, is $274. Novo Nordisk’s own self-pay pen for Wegovy (same molecule, different box) starts at $199 a month. What insurers and the companies that manage drug benefits for them actually pay, after the money that flows back from the manufacturer, is not in any source I have. That number is the real price, and it is the one nobody prints.</p>

What the Ozempic price on the sticker actually says</h2>
Let’s read that DrugPatentWatch sentence slowly, the way a lawyer reads a contract they are being paid by the hour to read (a job I would take, frankly).</p>
“The 2024.” The price has a year attached. This is the first clue that it is not a fact about the drug. Semaglutide is the same molecule in 2024 as it is in 2027, when Medicare pays $274 for it. The molecule did not get 71% cheaper to make. The year changed and a law got involved.</p>
“List price.” Not “price.” A list price is the price on the list. There are other prices. They are not on the list.</p>
“Of Ozempic.” Of Ozempic specifically, not of semaglutide. Novo Nordisk sells the same active ingredient as Ozempic, Wegovy and Rybelsus, and they have different prices, because they are different products in the sense that matters, which is the commercial sense.</p>
“Was $959.” Was. Past tense. Fine.</p>
“Per 30-day supply.” Here I feel like the sentence is being honest with us. It is not per pen or per milligram. It is per month of being on the drug, which is how patients experience the cost, and also how a subscription works.</p>
“In the United States.” This clause is doing a lot of work. In India the same company cut the price of Ozempic by 36% about ten days after generics showed up in March 2026. The price is a fact about a country, a year and a competitive situation. It is not a fact about the medicine.</p>
So read literally, the sentence says: in one country, in one year, on one list, this was the number. Which is true. It is just very carefully not saying anything else.</p>

Who pays the list price, basically</h2>
Here is the mechanism in plain words. The manufacturer announces a high price. Then a large buyer (an insurer, or the company that runs drug benefits for an employer’s health plan) says it would like to pay less. The manufacturer says fine, but you pay the high price at the pharmacy counter, and later I will send you a check for part of it, provided you put my drug on your list of covered drugs and make it easy to get. The buyer agrees. Everybody reports the high number in public and settles up in private.</p>
The official name for the check is a rebate. The companies in the middle are pharmacy benefit managers, or PBMs. The list of covered drugs is a formulary (a word that sounds much calmer than the fights about it).</p>
I mean, you can see the appeal. Imagine a meeting at a PBM, invented by me for illustration:</p>
“Hey guys, Novo raised the list price.”</p>
“Great, what’s the rebate?”</p>
“Bigger.”</p>
“Great.”</p>
That meeting is made up. The incentive it describes is the general structure of the business: if a middleman’s compensation is tied to the size of the discount it extracts, then a higher starting price makes for a bigger, more impressive discount. On the other hand, nobody publishes the actual Ozempic rebate, so I can’t tell you whether it is small, enormous, or somewhere in between. That part is not settled by anything public.</p>
The people who get hurt by this structure are the ones whose costs are computed off the list price: someone paying cash, or someone whose insurance has them pay a percentage of the drug’s price before or instead of a flat copay. For them the fictional number becomes quite real. The fiction is load-bearing for exactly the people who are not in the room.</p>

What the other prices reveal about the list price</h2>
The best way to see that the sticker is mostly a negotiating position is to look at all the other prices the same company is willing to accept for the same molecule.</p>
The Medicare price. Semaglutide was included in the second round of Medicare drug price negotiations under the Inflation Reduction Act, and the result is $274 per 30-day supply from January 1, 2027. DrugPatentWatch says this “represents a 71% reduction from the 2024 list price of $959.” Which is true arithmetically, and also a slightly funny way to put it, because it measures a real price against a list price, a bit like measuring your height against the tallest number on a ruler.</p>
The direct-to-patient price. As of October 21, 2026, Disclosed Labs reports Novo Nordisk’s NovoCare Pharmacy self-pay price for Wegovy starts at $199 a month for the pen and $149 for the pill. Wegovy is semaglutide. The pen is a pen. The company, selling directly and skipping the middle, is willing to start at roughly a fifth of the Ozempic sticker.</p>
The compounders’ price. When US compounding pharmacies were selling injectable semaglutide, they averaged about $230 a month, “more than half off the branded drug prices,” per MedPath. (That is another site’s beat, and a legal story more than a price story.) But it tells you the market had a guess about what the stuff is worth when nobody is printing a list.</p>
If you line these up, $959 is the outlier, not the anchor. It is the MSRP on the window of the car, and everyone who has bought a car knows what the MSRP is for. It is for the salesperson to walk you down from.</p>

What generics do to the sticker</h2>
The list price also exists because nobody else is allowed to sell semaglutide in the United States yet. The core compound patent runs to December 5, 2031 (exactly 14 years after Ozempic’s approval on December 5, 2017), and Novo Nordisk reports 2032 as the effective expiry. Apotex got the first FDA tentative approval for a generic Ozempic on April 10, 2026, which means approved-ish, pending the patents. Novo has settled litigation with seven would-be generic makers, and “all settlement terms are confidential,” which is the corporate version of what happened at the bachelor party staying at the bachelor party.</p>
India is the preview. Over 40 generic semaglutide brands launched there on March 21, 2026, the day after the patent expired. About ten days later Novo cut Ozempic by 36% and Wegovy by 48%. Notice the speed. A list price that could drop a third in ten days was not, I suppose, a price the company needed in order to keep the lights on.</p>
The US version will probably be gentler. One source says US biosimilar or generic peptide drugs typically get 15 to 40% price reductions, against the 80 to 90% common for ordinary pills, and when generic Victoza launched, Teva’s version was about 16 to 17% cheaper than the brand. FDA data show generics running about 39% below brand with one generic maker and more than 95% below with six or more. So the answer depends on how many show up, which is not settled.</p>

Why the sticker number survives</h2>
It is worth asking why a company keeps a list price that its own other channels so cheerfully undercut. The honest answer is that the list price is useful to almost everyone who sets it. It is the base from which rebates are measured, the number that makes a discount look big, and the opening offer in every negotiation, including the government’s.</p>
Price changes come with their own vocabulary, too. Eli Lilly raised the UK price of its rival drug Mounjaro, a move reported by Pharmaceutical Technology as meant to “better reflect market conditions.” Translated into flat English: we found out people would pay more, so now they will.</p>
I write about drug prices for a living, which mostly means reading other people’s sentences about prices very slowly and then writing longer sentences about them. lol. It is a strange job. But the slow reading is the whole thing here, because the sentence everyone quotes is precise about exactly one thing: that it is a list price. Every other price in this article is lower. Most of them come from the same company.</p>
The list price is the price you pay when nobody is negotiating for you.</p>

Semaglutide in Canada: The Patent That Lapsed Over a Fee

2026-11-01T00:00:00+00:00

Novo Nordisk, which makes Ozempic, had a Canadian patent on semaglutide, the molecule inside it, and in 2019 it did not pay a maintenance fee of CAD $250 to keep that patent alive. The patent, CA 2601784, lapsed permanently. On April 28, 2026, Health Canada authorized a generic semaglutide injection from Dr. Reddy’s Laboratories, making Canada the first G7 country to approve a generic version of the drug, and generic launches began from mid-May 2026.</p>

So the short version of the semaglutide Canada story is this. Generic copies of Ozempic are approved there now: Dr. Reddy’s first, then Apotex on May 1, 2026, then on June 29, 2026 a generic version of Wegovy from Apotex called Sevmia. More filings are in the queue. A large part of the reason this happened in Canada years before the United States is a fee of about the size of a nice dinner (CAD $250 is roughly $180 US, depending on the day).</p>

Surely nobody loses a patent over $250?</h2>
This is the sensible reaction, and it deserves to be taken seriously. Novo Nordisk is a very large company. Ozempic was Canada’s best-selling drug in 2025, with $2.9 billion in sales (Canadian dollars, so roughly $2 billion and change US), more than three times the next best-selling drug, and over a million Canadians were on it when the generic was approved. That is a reasonably popular product. The obvious assumption is that a company with that much at stake has a person whose entire job is paying small fees on time, and a second person checking the first person, and a calendar reminder, etc.</p>
And the system agrees with you, sort of. It assumes people forget stuff. Before October 30, 2019, if you missed a maintenance fee deadline on a granted Canadian patent, you had 12 months as of right to pay the missed fee plus a late fee before the patent actually lapsed. The late fee, per a guide to patent maintenance fees, is CAD 150 (as of 2024 and 2025). A podcast from ipCapital Group titled its episode “Ozempic Makes Billions. Its Canadian Patent Fee Was $450,” which gets at the general scale of things: whatever the exact all-in number was, it was a few hundred Canadian dollars.</p>
So the objection is right that there was a safety net. The weird part is that the patent fell through it anyway.</p>

How a Canadian maintenance fee actually works</h2>
Here is the mechanism stated as plainly as possible. Canada lets you own an invention for about twenty years, but it charges you rent every year to keep owning it, and if you stop paying rent, the invention stops being yours and becomes everyone’s. This is called a patent maintenance fee.</p>
The rent goes up as the patent ages. As of 2025, standard Canadian fees were CAD 130.50 a year for the 2nd through 4th anniversaries of filing, CAD 289.19 for the 5th through 9th, CAD 362.27 for the 10th through 14th, and CAD 651.46 for the 15th through 19th. The logic is sort of elegant: early on, when you do not know if your invention is worth anything, it is cheap; later, if you are still paying, presumably it is worth something.</p>
The mundane comparison is a storage unit. You rent a locker, you pay monthly, and if you stop paying, the facility sends a notice, waits a while, and then auctions off the contents. Nobody at the storage facility asks whether the locker contains old furniture or the original manuscript of a bestselling novel. The fee is the same either way. Canada’s patent office is the storage facility, and in this case the locker contained the active ingredient of the country’s best-selling drug.</p>
A reinstated application, for what it is worth, requires a reinstatement request, the missed fee, a reinstatement fee and late fee, and a demonstration of “due care.” That last phrase is where Canadian patent lawyers spend a lot of their time, and it is the kind of thing I would explain at much greater length if anyone had ever asked me to at a party (nobody has).</p>

Was it a mistake?</h2>
I don’t know, and the facts here do not settle it. The UK law firm Reddie & Grose ran a piece under the headline “A Key Ozempic Patent Lapses in Canada - Deliberate or a Mistake?” which is the honest framing: the question mark is doing real work. Fortune reported on the lapse on June 17, 2025, and Patent Lawyer Magazine titled its own article “highlighting the need to maintain patent protection in Canada,” which is the profession’s polite way of saying “please pay your fees.”</p>
The deliberate theory is not crazy, for instance. Companies drop patents all the time when they think the patent is not worth the rent, or when they think other patents cover the same ground. If all the fees had been paid, CA 2601784 would have expired on March 20, 2026 anyway. And Canada also has data protection, a separate thing that keeps generics from relying on the brand’s clinical data for a while; for semaglutide that ended January 4, 2026. So the window in which the patent alone was doing anything was narrower than the headlines suggest.</p>
Here is the stranger part. That patent had a supplementary protection certificate, a sort of bonus term Canada grants for drugs, which would have extended protection to March 20, 2028. The lapse voided it. One source describes this as “opening the market nearly two years earlier than expected.” So the $250 was not really buying the remaining years of the patent. It was buying the right to the bonus years, and the bonus years were the expensive part.</p>
You can picture the meeting, if there was one. “Hey, do we still need the Canadian one?” “I think the other stuff covers it.” “Cool, skip it.” That is invented, to be clear. It is not settled whether anything like it happened.</p>

Who has filed with Health Canada, and who is approved</h2>
Once the patent was gone and data protection ran out, the gate was Health Canada’s review. The line at that gate has been long and somewhat blurry in its count, depending on when you check. As of July 2025, five generic semaglutide submissions were under review. As of May 1, 2026, after the second approval, Health Canada was reviewing seven other submissions. As of June 29, 2026, it was reviewing six others. One report puts the total at nine, including Sandoz, Apotex, Teva, Aspen Pharmacare and Taro Pharmaceuticals.</p>
The approvals so far go like this. Dr. Reddy’s got the first, on April 28, 2026, a generic version of Ozempic for once-weekly treatment of adults with type 2 diabetes. Apotex got the second on May 1, 2026, same indication, within days. Apotex announced it under the headline “Apotex Becomes the First Canadian-Based Pharmaceutical Company to Receive Health Canada Approval for a Generic Equivalent of Ozempic,” which is a very precise way to be first at something when you finished second (press releases reward careful use of adjectives). Then on June 29, 2026, Health Canada authorized Sevmia, Apotex’s generic version of Wegovy, the first generic semaglutide for weight loss and the third generic semaglutide overall.</p>
That last one is a little puzzling. One source said Wegovy (semaglutide at the 2.4 mg weekly dose) remained patent-protected as of Apotex’s May approval, and pen device patents for semaglutide in Canada are reported to run to at least 2033. By late June, Sevmia was authorized anyway. The facts here do not explain how those pieces fit together, and it would be easy to guess wrong.</p>
The Dr. Reddy’s piece also has an Indian subplot. In December 2025, a single judge of the Delhi High Court refused Novo Nordisk an injunction against Dr. Reddy’s, which let Dr. Reddy’s manufacture semaglutide for export to markets where the patent had already lapsed. Canada was one of those markets. (India’s own compound patent lapsed on March 20, 2026, which is a story for another article.)</p>

What generic semaglutide in Canada means for prices and cross-border buyers</h2>
The price signal so far is that Sandoz has said it may offer generic semaglutide discounts of up to 70% in Canada. “Up to” is carrying its usual weight, and whatever the actual shelf prices turn out to be is not settled by these facts.</p>
The cross-border question is the one Americans actually care about. Canada is in the early wave of semaglutide patent expiry in 2026, alongside India, China, Brazil and South Africa. The UK, the big EU markets and Japan are around 2031. The United States is in the late wave, 2032 to 2033. So for the next several years there will be a cheap legal generic a short drive from Buffalo and an expensive patented brand on the near side of the border, which is the sort of arrangement that has a whole genre of road-trip movies waiting for it.</p>
What that means legally for an American who wants the Canadian product is a separate question from what it costs, and these facts do not answer it. A drug being generic in Canada does not make it generic in the US, where the patents still run, and what happens to any individual buyer, pharmacy or importer at the border depends on US rules this article does not cover. The point is that the price gap is created by patent dates, and the patent dates are set country by country.</p>
So the biggest drug in Canada was protected, in the end, by a calendar. Calendars are not that strong.</p>

China and Brazil: The Other Two Big Semaglutide Markets Going Generic

2026-11-01T00:00:00+00:00

On March 20, 2026, the core patent on semaglutide, the molecule inside Ozempic and Wegovy, expired in China and in Brazil on the same day. Brazil approved its first generic version in May. China, as of October 2026, had approved zero.</p>

So the short answer for anyone searching semaglutide china is this: the compound patent is gone, but a separate layer of protection for Novo Nordisk’s clinical trial data runs to approximately April 2027, and it blocks generic approval until then. The line behind that barrier is long. By the day the patent expired, 12 domestically made semaglutide generics from 10 Chinese companies had filed for registration with the NMPA, China’s drug regulator. Brazil, meanwhile, refused Novo Nordisk’s request to extend its patent term, and as of September 2026 its approved generics were diabetes pens only.</p>

The dumb version: the patent ends and the pens show up</h2>
Here is the dumb version of how a drug goes generic, and I mean “dumb” as a compliment. A company invents a molecule and gets a patent. The patent lasts a fixed time. When it ends, other companies make the same molecule and sell it for less. That is the whole system, and it fits on an index card.</p>
The question presented is whether a generic manufacturer may sell semaglutide on the date the patent expires. The record shows that in India the answer was, in practice, no: over 40 generic brands launched on March 21, 2026, which is the day after. (The patent is entitled to its final day, the same way a hotel guest is entitled to the room until checkout.) Prices went from roughly $100 to $125 a month for Ozempic to roughly $20 to $50 for generics, and Novo Nordisk cut Ozempic by 36% and Wegovy by 48% within 10 days.</p>
That is the dumb version. It works.</p>

The sophisticated version: semaglutide in China waits for its data</h2>
China runs the same race with an extra hurdle. When an originator runs years of clinical trials, regulators in many countries protect that data for a period, meaning a generic company cannot simply point at Novo Nordisk’s trials and say “what they said.” In China that period for semaglutide runs to approximately April 2027. The industry calls this “data exclusivity,” which sounds like a relationship status, and for roughly five more months it is one.</p>
I assume the conversations inside Chinese drug companies on March 20 went something like this (invented, but I feel like it is close):</p>
“The patent expired.”</p>
“Great, so we launch tomorrow?”</p>
“No. Now we wait for the data to expire.”</p>
“Data expires?”</p>
“In April. Approximately.”</p>
Meanwhile everyone files paperwork, because being early matters. On February 25, 2026, Jiuyuan Genetic Biopharmaceutical said in a Hong Kong Stock Exchange filing that the NMPA had accepted for review its application for Jikeqin, a generic Wegovy. Hybio Pharmaceutical and Jiangsu Sinopep-Allsino Biopharmaceutical are also working on their own launches. Back in June 2024 there were at least 15 Chinese versions in development; IQVIA now counts 17 that have reached Phase III trials or the pre-market application stage, with 9 of them running trials specifically in obesity.</p>
Then there is the classification question, which is where the sophisticated version earns the name. Qilu Pharmaceutical and Changchun Bcht Biotechnology registered their semaglutide as Class 2.2 drugs, “modified new chemical drugs.” Jiuyuan Gene and Xibeijiang Pharmaceutical (part of Livzon Group) registered theirs as Class 3.3, generic versions of therapeutic biological products. Same molecule. Two filing cabinets. To be fair, a peptide does sit between chemistry and biology, so this is less a contradiction than a molecule refusing to fill out a form.</p>
Let me dwell for a second on 12 drugs from 10 companies. Twelve is more than ten. That means at least one company looked at a market with no approved generics yet and decided the right number of applications to have pending was more than one. Hedging against your own regulator’s preferences is a sort of thing I find quietly admirable.</p>
Why would you file twice? Because of the prize at the front of the line. The industry outlet VCBeat put it this way: “securing ‘first generic’ status establishes a unique competitive position that is difficult for competitors to shake.” There is also a formal rule: China’s 2021 patent linkage measure grants 12 months of market exclusivity to the first small molecule generic applicant that successfully invalidates a listed patent and gets approved. Whether that rule reaches a peptide whose patent simply expired, rather than being invalidated, is not settled by anything here, and I would not bet my column on it.</p>
Now push the incentive forward. Say (this is made up) every company files in every available class, then files a reformulated version, then files the reformulated version in the other class. By April 2027 the NMPA could be holding more semaglutide applications than there are vials of it in Shanghai. The first approval would still go to one of them. The rest would be very well documented.</p>

Brazil, where the regulator declined to add time</h2>
Brazil is closer to the dumb version, which is to say it moved fast. Its core patent expired March 20, 2026. Novo Nordisk asked for a patent term extension (the pharmaceutical version of asking the teacher for a few more minutes on the exam), and ANVISA, Brazil’s health regulator, refused. Brazil’s patent linkage system only blocks a generic approval if a valid patent sits in its official database, and after March 20 there was not one doing that job. The first generic approval came in May.</p>
That speed is unusual. The OzemPro Blog, which tracks Brazilian launches, says the gap between patent expiry and first generic approval in Brazil “has historically averaged 2 to 4 years.” This one took about two months. It is like a marathon where the field usually waits at the line for a while after the gun, and this time everyone simply ran.</p>
The catch is the indication. The first approvals were diabetes pens, not weight loss products, and when the weight loss side opens is not settled. On price, the same blog says that when multiple generic manufacturers enter Brazil, “price reductions typically reach 50-80% below the originator price.” How many manufacturers Brazil ends up with, and how fast, is the variable that decides where in that range it lands.</p>

How big emerging markets end up setting the price everywhere else</h2>
IQVIA lists eight markets losing semaglutide exclusivity in the 2026 first wave: Canada, Brazil, China, India, Mexico, Turkey, Saudi Arabia and South Africa. The EU and UK are protected until approximately March 2031. In the US, litigation settlements point to generic entry around 2032, with follow-on patents running to 2033. So for about five years, a large share of the world buys semaglutide at generic prices while the richest markets do not.</p>
That gap is where emerging markets start to matter beyond their borders. In July 2025, according to Pearce IP, Dr. Reddy’s Laboratories announced plans to launch a generic Wegovy in 87 countries in 2026, starting with Canada, India, Brazil, Turkey and other emerging markets. A company selling into 87 countries is not pricing for one of them. And once China opens, 17 serious candidates competing in a market VCBeat called “an untapped market with enormous potential” for weight loss will set a reference point for what semaglutide costs to make and sell at scale.</p>
What that does to American or European list prices before 2031 is, honestly, not settled by these facts. Novo Nordisk’s Indian price cuts within 10 days show the originator will respond country by country. Whether that pressure travels is a separate question. (Look, I write about finance for a living, which mostly means reading footnotes about dates and then having opinions about them.) It is also worth noting the market leader by 2026 was Eli Lilly, whose tirzepatide is protected in the US until 2036, so the competitive story in rich countries is not only about semaglutide.</p>

Where the two roads meet</h2>
So here is the comparison. India took the dumb road: patent ends, pens arrive the next morning, prices fall. Brazil took a slightly longer one: patent ends, extension refused, diabetes pens in May, weight loss later. China took the scenic route: patent ends, data protection holds, two registration classes, a first-generic race, 17 candidates queued at the barrier. I guess all three arrive at the same place, a crowded market with falling prices. China just gets there around April 2027 instead of March 21, 2026.</p>
The patent died on the same day in all three countries. I suppose the funeral is still in progress in China, with a lot of guests already in the parking lot, engines running. Which means that for about a year, the most valuable piece of intellectual property in Chinese semaglutide was a calendar, and it was the one thing nobody filed an application for.</p>

What Semaglutide Costs Around the World, and Why the Gap Is So Large

2026-11-01T00:00:00+00:00

I spent a good part of this week converting the price of one molecule into five currencies, which is not a hobby anyone chooses. If you came here asking about semaglutide cost, the plain answer is that there is no single number. There is a price in India, a different price in Canada, a much later generic date in the US, and the gaps between them come from patents, extensions and who is doing the negotiating. They do not come from what the stuff costs to make.</p>

Some numbers. In India, before generics, Ozempic cost about ₹8,800 to ₹11,175 a month (roughly $100 to $130) and Wegovy up to ₹16,400 (roughly $190). After more than 40 generic brands launched on March 21, 2026, generics sold for ₹1,800 to ₹4,200 a month (roughly $20 to $50). In Canada, Sandoz projected generics would take monthly costs from about CAD 1,000 to CAD 300 or less (roughly $720 down to roughly $215). In the US, litigation settlements point to generic entry around 2032, and my facts do not include a settled US brand price to set beside these, so I will not make one up. A 2024 JAMA report put the cost of producing a month’s supply of semaglutide powder at 7 cents.</p>

Why the price has nothing to do with the cost of making it</h2>
Start with the reasonable version. A company spends years inventing a drug. Once invented, the drug is cheap to make: about 7 cents of powder a month, and Chinese ingredient makers could reportedly sell it to compounders for up to about 49 cents and still collect seven times their cost. (The pen, the refrigeration, the regulators, etc., cost more than the powder, in fairness to everyone.) So the price of the drug is not the cost of the drug. The price pays for the invention.</p>
That is the patent bargain, and it’s fine. The government lets you be the only seller for 20 years, you charge a lot, and then the monopoly ends and the price drifts down toward the 7 cents. Novo Nordisk filed the core semaglutide patent on March 20, 2006, which gives a baseline expiry of March 20, 2026.</p>
Commercially, the bargain worked. IQVIA calls semaglutide (Ozempic and Wegovy combined) “the world’s second-best-selling prescription medicine,” with $26 billion in sales in 2024, growing about 40% a year. That is a lot of inventing paid for.</p>

How each country gets its own patent clock</h2>
Step two. Patents are national. So instead of one monopoly ending on one day, you get a monopoly that ends in different places on different days, and the price of a single molecule becomes a function of geography.</p>
The rough schedule: an early wave in 2026 (India, China, Brazil, Canada, South Africa), a mid wave around 2031 (the UK, Germany, France, Italy, Spain and Japan), and a late wave in 2032 to 2033 for the US. The difference is extensions. The European Union granted a Supplementary Protection Certificate adding five years, to 2031. The UK one runs from March 19, 2026 to March 19, 2031.</p>
In the US, the compound patent got what the law calls “patent term restoration,” a 1,040-day extension to December 5, 2031. Translated: the government agreed that time spent waiting for approval did not really count, and handed back about two years and ten months. Novo Nordisk’s own 2025 Form 20-F gives the US compound expiry as “2032,” with secondary patents running to 2038 and one Wegovy patent to May 13, 2040.</p>
The early-wave countries are not uniformly early, either. Brazil’s regulator, ANVISA, refused Novo’s extension request and approved the first generic in May 2026 for diabetes pens, though one pricing guide projects generic pens reaching Brazilian pharmacies around 2028 to 2030. China’s compound patent expired, but data protection runs to about April 2027, with at least 17 Chinese manufacturers in Phase III or pre-market stages. In India, a tablet formulation patent runs to 2031, so the pill version stays protected even though the injection does not.</p>
So a patient in Mumbai and a patient in Ohio take the same molecule on very different timetables. Same chemistry. Different calendars.</p>

What semaglutide cost does when 40 brands show up</h2>
India is the clean experiment. The patent lapsed on March 20, 2026. On March 21, more than 40 brands launched. Within 10 days, Novo cut Ozempic by 36% and Wegovy by 48%. By April, generics had taken 50% of India’s semaglutide sales by value.</p>
Note what did not change in those 10 days: the cost of making the drug. The powder still cost what it cost. What changed was the number of sellers. That was the whole difference.</p>
It must have been an exhausting week and a half for Novo’s pricing team, discovering under such pressure that the drug could be nearly half as expensive. Very fast work. Impressive, really.</p>

How a country loses its patent over a fee</h2>
Step three is where it gets weird. Patents also have to be maintained, which means paying renewal fees, which means somebody has to remember. In 2019, Novo did not pay a CAD 250 (roughly $180) maintenance fee on Canadian patent CA 2601784, and the patent lapsed permanently. That also voided a supplementary protection certificate that would have run to March 20, 2028. Health Canada approved Dr. Reddy’s generic on April 28, 2026, the first G7 country to do so, in what is reportedly the world’s second-largest semaglutide market.</p>
In a heist movie the vault has lasers and a guard. Here, the vault was protected by an invoice. (I write about patent maintenance fees for a living, which is the sort of sentence that ends conversations at dinner.)</p>
The patent firm Reddie & Grose titled its write-up on this “Deliberate or a Mistake?”, and I don’t know. The obvious reading is that somebody missed a payment, the way people miss payments, possibly while someone in the office was saying, “hey, did the Canada one go out?” (a line I have invented). The other reading is that a company with dozens of patents on one drug decided this particular one was not worth $180 in 2019, before anyone knew how big the drug would become. The facts here do not say which. Either way, a fee smaller than a monthly prescription set the generic date for a whole country.</p>

Where reference pricing takes the price next</h2>
Now the last step, and the dumb endpoint. Suppose countries stop setting prices on their own and start pointing at each other. Here is an invented scenario. Country A says it will pay the lowest price charged anywhere in a basket of rich countries. Country B, which is in the basket, says the same thing. So does C. Now every price is defined as some other country’s price. The company, for instance, could respond by raising prices in B so A’s reference goes up, or by delaying launch in B so there is no B price at all. Push it far enough and the drug has no price, only a circle of countries each waiting to see what the others pay. Which is sort of where the arguments already go.</p>
The real world is partway down that road. Ozempic, Rybelsus and Wegovy were picked for the second round of Medicare drug price negotiation under the Inflation Reduction Act. One study re-estimating Medicare spending on semaglutide for 2026 to 2035 found base-case savings of $463 million under the negotiated price, rising to $2.63 billion under “Most Favored Nation” pricing combined with generic entry assumptions. Most Favored Nation is the circle: tie what Americans pay to what other countries pay.</p>
The point is that foreign prices stop being foreign. Under a regime like that, an Indian price cut or a Canadian generic is no longer just a local event; it is potentially an input into a US number. Exactly which countries count, and how the formula works for semaglutide, is not settled in what I have here.</p>
If the basket ends up including Canada, then some piece of what Medicare pays for semaglutide will trace back to a roughly $180 fee nobody paid in 2019.</p>

Semaglutide Patent Expiration: How a Molecule Patent Actually Ends

2026-11-01T00:00:00+00:00

I used to think a patent worked like a carton of milk: there is a date stamped on it, and after that date the thing stops being yours alone. For semaglutide, the molecule in Ozempic, Wegovy and Rybelsus, the stamped date was March 20, 2026. Novo Nordisk filed the core compound patent family on March 20, 2006, a patent runs 20 years from filing (this is the one part of patent law that fits on a napkin), and so in countries without an extension the compound patent just ended that day. It did end, in India, China and Brazil among other places.</p>

In the United States, semaglutide patent expiration works differently, and the stamped date is wrong. The patent expired in 2026. Well, no. The US compound patent, US 8,129,343, was originally due to run out in 2026, but after an adjustment and an extension it now runs to December 5, 2031, per the FDA Orange Book. Novo Nordisk, on the other hand, says in its 2025 Form 20-F that the US compound expiry for Ozempic, Rybelsus and Wegovy is 2032. Secondary US patents are reported to run to 2038 (one law firm summary says 2033), and one estimate puts a US generic Rybelsus at May 2, 2034. The European Union granted a Supplementary Protection Certificate to 2031, and Japan’s protection was extended to about 2031 too.</p>

When the semaglutide patent expires, and why there are several answers</h2>
The reason there is no single date is that “the semaglutide patent” is not one thing. There is the compound patent, which covers the molecule itself. Then there are formulation patents, which cover particular ways of turning the molecule into a medicine, and device patents, which cover the pen you inject it with. Each has its own filing date and its own end.</p>
This is like the end of a Marvel movie. The credits roll, half the theater leaves (the patent lawyers never leave), and the people who know better stay seated, because there is always another scene.</p>

What the compound patent covers, and what it does not</h2>
The compound patent is the big one, in the sense that it covers semaglutide, the molecule. When it ends, a competitor may make the molecule. That is basically the whole of what it gives you. It does not let you copy any particular tablet or pen if those are covered by their own patents.</p>
Here is the cleanest example. Rybelsus is a semaglutide tablet, and getting a peptide through the stomach is hard, so Novo uses an absorption enhancer called SNAC. The website Generic Guide reports that “a semaglutide oral tablet formulation patent covering the SNAC absorption enhancer in a specific range runs to 2031 in India, blocking generic oral semaglutide (Rybelsus equivalent) even after the injectable compound patent expired in March 2026.” Two Indian manufacturers then gave the Delhi High Court undertakings that their tablets fall outside that concentration range. I assume the hearing went something like: “Your Honor, our tablet contains SNAC. Just not that SNAC.”</p>
Pens work the same way. In Canada, generic semaglutide became available from mid-May 2026 (the reason Canada got there early is its own story, told elsewhere on this site), while pen device patents there are reported to run to at least 2033.</p>
Here is a made-up scenario, purely made up, to show where this goes. A generic company gets the molecule in 2026, but the pen is patented, so it designs a new pen. The cap is patented, so it designs a new cap. The click the pen makes when it doses is patented, so the new pen is silent. The box has a patented fold. Eventually the generic arrives as a silent, capless, unboxed object that a patient must assemble from a kit. No real drug is like this, I think.</p>

How a 20-year patent becomes a 26-year one</h2>
In the US, two separate mechanisms push the compound date out. A Patent Term Adjustment compensates for delays at the patent office, and one source reports Novo received 1,114 days of it for its semaglutide drug substance patents. A Patent Term Extension compensates for time lost waiting for drug approval, and DrugPatentWatch reports that US 8,129,343 “received a 1,040-day patent term extension from the USPTO.” Together, they are why 2026 became 2031.</p>
(I tried to add those days to March 20, 2026 and land on December 5, 2031, and could not make it work, which says something about either the sources or my arithmetic, and the smart money is on my arithmetic.) How exactly the two figures combine, and why Novo says 2032 when the Orange Book says 2031, is not settled by the sources here.</p>
The extension has limits. Under 35 U.S.C. 156, an extension cannot leave more than 14 years of exclusivity after approval, and only one patent per active ingredient product may be extended. So Wegovy and Rybelsus could not get a second extension on the same compound patent. It is like a library card that lets you renew one book, once, and never past a fixed date. You pick carefully. For comparison, Eli Lilly’s tirzepatide compound patent got a 129-day extension.</p>
Other countries made different choices. Brazil’s regulator, ANVISA, refused Novo’s extension request, and the first generic was approved in May 2026. China has no extension that applies, because Ozempic was approved there in April 2021, and the patent law amendment that created extensions took effect June 1, 2021, without reaching back. Missed it by weeks. China does have data protection running to about April 2027, and as of October 2026 it had approved zero generics, though at least 17 Chinese manufacturers are in late trials or applications.</p>
There is also pediatric exclusivity, a separate add-on that sometimes tacks months onto a drug’s protection. Whether it attaches to any semaglutide date is not something these sources address, so I will not pretend it is settled.</p>

The Orange Book and the 30-month line</h2>
The Orange Book is the FDA’s list of patents a brand company says cover its approved drug. Listing matters because of the 1984 Hatch-Waxman Act, which lets a brand company trigger an automatic 30-month stay of a generic application’s approval by listing patents there. So a listed patent is not just a patent. It is a patent with a waiting period attached, sort of like a queue where anyone already standing in it can make the person behind them wait two and a half years.</p>
DrugPatentWatch’s article on this is titled “Own the Market: How Brand Companies Strategically List Patents in the FDA Orange Book,” and I feel like the word “strategically” is carrying a lot of weight in that headline (I’m sure it just means thoughtfully).</p>

Three ways to read all these dates</h2>
There are, roughly, three ways to read this.</p>
The first reading is that the compound patent is the real date and everything else is noise. To be fair, there is a lot to this. In India, Brazil and Canada, once the molecule was free, generic injectables showed up within months. The formulation and device patents slowed specific products but did not stop the category.</p>
The second reading is that the real date is whatever the extension rules say, which makes this a story about legislatures. Brazil refused an extension and got generics in 2026. China’s extension rule arrived a few weeks too late. The US and EU granted extensions and are at 2031 or so. The molecule is identical everywhere; the end dates track policy. That seems like a reasonable thing for policy to decide, I suppose.</p>
The third reading is the least comfortable one. It says the molecule’s expiry is not really the event at all. In the US, after the compound patent ends in 2031 (or 2032), there are secondary patents to 2033 or 2038, a tablet estimate of 2034, and an Orange Book that can turn each listed patent into a 30-month wait. On this reading a drug does not go off patent. It goes off patent one piece at a time, and the order of the pieces is set by lawyers, and the people waiting for the price to fall cannot tell from the outside which piece is the last one.</p>
The carton does have a date on it. So do the cap, the spout and the carton itself, and in America the cap might be good until 2038.</p>

Wegovy's Generic Name Is Semaglutide. That Does Not Make It Generic.

2026-11-01T00:00:00+00:00

If you have a Wegovy pen in the fridge and you turn the box over to read the small print, you will find a second, plainer word: semaglutide. That is the Wegovy generic name, and it is also the generic name of Ozempic and of Rybelsus, because all three are the same molecule, made by the same company, Novo Nordisk, and sold under three different brand names. In India, for instance, semaglutide was available before March 20, 2026 only as Ozempic, Wegovy and Rybelsus, all of them Novo’s. Ozempic is the type 2 diabetes injection, Wegovy is the weight-loss injection (semaglutide at the 2.4 mg weekly dose for obesity), and Rybelsus is the tablet.</p>

What the generic name does not tell you is whether a generic drug exists. Those are different things. As of September 2026, generic semaglutide was on sale in India, Canada, Brazil, South Africa and Saudi Arabia, while the US, the EU, the UK and Japan stay protected until roughly 2031 to 2032. In the US, brand-name Ozempic or Wegovy costs $935 to $1,349 a month without insurance. Knowing the name of the molecule is free. The molecule is not.</p>

What a “generic name” means, stated with excessive care</h2>
Here is the vocabulary, set out with the solemnity of the definitions section of a credit agreement, because in some sense that is what it is. “Generic name” means the name of the active substance, which belongs to nobody. “Brand name” means the name a company chose to sell that substance under, which belongs very much to somebody. “Generic drug” means a separate product, approved as a copy of a particular brand, usually once that brand’s protections have run out. A generic name is a word. A generic drug is a product. (The definitions section is always where the real fights happen.)</p>
The European Medicines Agency says a generic medicine “contains the same active substance(s) as the reference medicine, is used at the same dose(s) to treat the same disease(s), but may differ in inactive ingredients, name, appearance, and packaging.” Notice what the copy is measured against. Not the molecule. The reference medicine, which is to say a brand. So when Health Canada approved Apotex’s weight-loss semaglutide on June 29, 2026, Canada.ca described it as “a generic version of the brand name drug Wegovy.” The generic is a copy of Wegovy, not a copy of the word semaglutide.</p>

Why the same molecule has three brands</h2>
There are, roughly, three ways to read this, and they get less comfortable as they go.</p>
The first reading is medical and regulatory, and it is basically tidy. A brand is a bundle: one molecule, one dose, one disease, one delivery format. Change the dose and the disease and you have, for regulatory purposes, a different product, the way Clark Kent and Superman are one guy with two job descriptions and a pair of glasses between them. Because a generic has to match dose and disease, there is a generic Ozempic and a separate generic Wegovy. In Canada, Dr. Reddy’s got the first generic semaglutide approval, for type 2 diabetes, on April 28, 2026; Apotex’s May 1 approval was a generic Ozempic; and Apotex’s weight-loss product, Sevmia, was the third generic semaglutide Health Canada approved. Three approvals, one molecule, sorted by which brand each one copies.</p>
The second reading is about price, and it is also tidy if you happen to be Novo Nordisk. Separate brands let you charge separate prices for the same substance. Before generics arrived in India, Ozempic cost about ₹8,800 to ₹11,175 a month (roughly $100 to $130) and Wegovy cost up to ₹16,400 (roughly $190). The doses differ, so that’s fine as far as it goes. But when more than 40 generic brands launched on March 21, 2026, the day after patent expiry, Novo cut Ozempic by 36% and Wegovy by 48% within 10 days. What is in a name? In this case, about 48%. Generic prices landed around ₹1,800 to ₹4,200 a month (roughly $20 to $50).</p>
The third reading can wait. First, the generics.</p>

Generic semaglutide has brand names too</h2>
You might expect a generic to be sold as “semaglutide,” in a plain white box, in a font chosen by a committee. It is not. As of October 8, 2026, 12 generic manufacturers had publicly launched semaglutide in India, selling 20 brands between them. Zydus planned to sell its Semaglutide Injection (15 mg/3 ml) under three names at once: Semaglyn, Mashema and Alterme. One product, three brands. Lol. In Canada the generic Wegovy is Sevmia. In China, Jiuyuan’s application for Jikeqin, a generic version of Wegovy, was accepted for review on February 25, 2026, though as of October 2026 zero generic semaglutides had been approved in mainland China, despite the compound patent expiring there on March 20, 2026.</p>
Somewhere there was a meeting. “Okay, it’s semaglutide, it’s cheaper, and it needs to sound like a moon nobody has visited,” someone said, and everyone wrote that down.</p>
This next part is invented. A generic maker gives each pen strength its own brand, then each pen color, then each pharmacy chain, then each day of the week, so that Tuesday’s injection is Semavora and Wednesday’s is Glyvessa, until the national brand registry has more entries than the country has patients and a doctor (and, presumably, the pharmacist) needs a lookup table to learn that eleven of the names are the same pen. The real number in India is 20 brands from 12 makers. That is a long way from the invented version. It is also a long way from one.</p>
Then there is Poviztra. In November 2025, before the patent expired, Emcure agreed to hook up with Novo Nordisk (commercially, with lawyers present) and co-market Wegovy under that second name. One reading is that Novo wanted more sales reps and more shelf presence before the crowd arrived, which is an ordinary thing for a brand to want. The other is that a second name for the original gives the original a second face to compete with, one that can be positioned without anyone touching the first face’s price. The facts here don’t say what Poviztra costs, so that second reading just sits there.</p>

What the generic name means in the United States</h2>
In the US, semaglutide is a generic name with no generic drug on sale yet. The machinery is moving: Apotex received the first FDA tentative approval for a generic version of Ozempic, announced April 10, 2026. “Tentative” is the operative word. It means approved, pending the patents getting out of the way, sort of thing.</p>
One exact number deserves a moment. The FDA treats peptide chains of under 40 amino acid residues as generic drugs, which is why semaglutide, at 31 amino acids, qualifies. So does tirzepatide, at 39. Thirty-nine. One residue under the line. Whether copies of a major weight-loss molecule travel the ordinary generic road is settled by a counting rule, and it clears by a single link in the chain. I mean, it is a long chain. You would think someone would round. Clearing the line does not make copying easy, either: demonstrating bioequivalence for injectable peptides carries a higher analytical burden than for small-molecule generics.</p>

The least comfortable reading</h2>
The third reading is that the name is the asset and the molecule is the part that wears out. A patent ends on a date. A brand doesn’t come with one. When generic entry happened in India, it did what it is supposed to do to price: generics took 50% of semaglutide sales by value by April 2026, and Novo cut hard. In Canada, the government notes that many generic medications are 45 to 90% cheaper than brand-name versions.</p>
On the other hand, generic entry did not produce a world of plain boxes labeled semaglutide. It produced Sevmia, Semaglyn, Mashema, Alterme, Poviztra and Jikeqin, and a market where “generic” mostly means “the cheaper brand.” The word semaglutide is the one name on the whole list that nobody is selling under.</p>
For an American payer, that is the uncomfortable part. Until roughly 2031 to 2032, the generic name is information, not an option, and the price is set by the brand. After that the price should fall, if India and Canada are any guide (how far is not settled). The thing on the formulary will still have a brand name, possibly several.</p>
The patent on semaglutide has an expiry date in every country; nothing in any of these filings gives one for the word Wegovy.</p>

The Wegovy Pill and Its Price Tag

2026-11-01T00:00:00+00:00

Novo Nordisk sells the pill version of Wegovy, to people paying out of pocket, for less than it sells the shot. According to Disclosed Labs, “As of October 21, 2026, the self-pay price for Wegovy via NovoCare Pharmacy starts at $149/month for the pill formulation and $199/month for the pen formulation.” The pill is oral semaglutide. The FDA approved it in December 2025 for chronic weight management, and in its 64-week trial it produced about 14% average weight loss. Same molecule as the pen. Different box.</p>

If you came here looking for a wegovy pill coupon, the available sources describe something else. They describe a self-pay price through Novo’s own pharmacy channel, not a coupon in the cut-it-out-and-hand-it-over sense. Whether a separate savings card stacks on top of the $149 is not something these sources settle. What they do settle is that $149 is a brand price, set by the company that holds the patents. There is no generic Wegovy pill in the US, and the patent dates say there will not be one soon.</p>

The Wegovy pill coupon question, read like a contract</h2>
The whole subject fits inside that one sentence from Disclosed Labs, so I am going to read it the way a lawyer reads an indemnity clause, slowly and with suspicion. (Reading single sentences too closely is most of my job, which is not a great sign.) There are five operative pieces.</p>
“As of October 21, 2026.” The sentence speaks for a single day. It makes no representation regarding October 22, and a careful reader shall not imply one. Prices like this are announced, not promised, and the date is the sentence being honest about that.</p>
“The self-pay price.” This is the price for people outside insurance, outside Medicare, outside any system with a professional negotiator. It is the price you get when the only party across the table from Novo Nordisk is one person with a credit card.</p>
“Via NovoCare Pharmacy.” The seller is the manufacturer’s own pharmacy channel. The line between “drug company” and “pharmacy” is, in this arrangement, a bit blurry, the way the line between a restaurant and the chef’s cousin who runs the wine list is blurry. That’s fine. It just means the price, the pharmacy and any savings offer all come out of the same building.</p>
“Starts at.” This is the phrase on every airline fare and every new-car ad, and it means the same thing here: at least one version of this product exists at this price, and the sentence does not say which one or what the others cost. Here is an invented scenario, clearly made up. A literal-minded patient reads “starts at $149” and asks to buy only the start. A literal-minded pharmacy ships the first pill of the month at the starting price and prices the second at the next tier, and the third at the tier after that, until by pill thirty the patient has climbed a staircase of tiers the sentence never mentioned (and the pharmacy has invented several new ones to keep up). Nobody would do this. The wording just leaves room for it.</p>
“$149/month for the pill formulation and $199/month for the pen formulation.” The pill is $50 cheaper. That’s the weird part.</p>

Why the self-pay price sits below Medicare’s</h2>
Ozempic, Rybelsus and Wegovy were included in the second round of Medicare drug price negotiations under the Inflation Reduction Act. The negotiated price for the three is $274 per 30-day supply, effective January 1, 2027, a 71% cut from the 2024 list price of $959.</p>
So in some sense the federal government, with a statute and a whole negotiating process behind it, ended up with a number higher than the one a person with a credit card can see from Novo. (The comparison is rough: the sources do not say whether the Medicare price covers the pill, and “starts at” is not “costs.”) Still. The biggest buyer in American health care bargained hard and landed $125 above the bottom of the self-pay menu.</p>
One reading is that this is a market-building price: get people onto the drug, and onto the pill, before anything cheaper exists, while the list price stays where it is for every insurer that pays it. The other reading is that the price is defensive, set at the point where people who would otherwise go elsewhere stop going elsewhere (compounding pharmacies, for instance, sold injectable semaglutide for an average of $230 a month). You can picture someone in a pricing meeting saying, “Okay, we’re under the compounders and under Medicare, is anyone going to ask why the pill is cheaper than the pen?” I don’t know which reading is right. They are not exclusive.</p>

Why the pill is not cheaper to make, for pricing purposes</h2>
The natural guess is that the pill costs less because pills are simple and pens are fiddly little machines. The sources here do not say what either one costs to make, and this site leaves manufacturing to others. But the guess is beside the point anyway, because in the US this price is not set by cost. It is set by exclusivity.</p>
The pill is semaglutide. So is the pen. So is Ozempic. They share the compound patent, US 8,129,343, extended through patent term restoration to December 5, 2031, and Novo said in its 2025 Form 20-F that the US compound expiry for Ozempic, Rybelsus and Wegovy is 2032. The extension rule is strict: DrugPatentWatch notes that “Wegovy and Rybelsus cannot receive a second extension on the same semaglutide compound patent.” One molecule, one extension.</p>
That cuts both ways. The pill does not get its own longer core monopoly, but it does not escape the shared one either. Secondary patents stretch to 2038, and one listed patent, “Semaglutide For Use In Medicine,” runs to May 13, 2040, though that listing names Wegovy and Wegovy Flextouch (the injectable products) and the sources do not say which patents, if any, read on the pill. Presumably someone will litigate that. Not settled.</p>

What generic entry did to Wegovy in India</h2>
India is the clearest picture of what happens when the patent actually ends. Over 40 generic semaglutide brands launched there on March 21, 2026, the day after expiry. On April 1, about ten days later, Novo cut the price of the Wegovy starting dose by 48%, and Ozempic by 36%. That followed an earlier cut, in November 2025, of up to 37%, which took the Wegovy starting pack from Rs 16,261 (roughly $190) to Rs 10,850 (roughly $125).</p>
By October 8, 2026, the lowest stated monthly price for generic semaglutide in India was Rs 1,290, roughly $15, for vials from Natco and Eris. Stuff gets cheap fast.</p>
So generic entry did not merely add cheaper options. It moved the brand. A 48% cut in ten days is not a company discovering that its costs fell; it is a company discovering that it has competitors. Canada is heading the same direction (Health Canada authorized Apotex’s Sevmia, a generic of the Wegovy injection, on June 29, 2026), which other pieces on this site cover. None of these generics is a pill, by the way. They are injections and vials.</p>

When a cheaper US pill could arrive</h2>
On the dates in these sources, a generic oral semaglutide in the US is a 2032 story at the earliest for the molecule, with the secondary patents an open question after that. Until then, the cheapest pill is the one Novo chooses to sell cheaply, through its own pharmacy, as of a given date, starting at a given price, or whatever the next dated sentence says.</p>
That makes the $149 price less like a coupon and more like a press release with a checkout button. It is real money and a real price, and it sits entirely at the discretion of the patent holder. In India, that discretion ended on March 21.</p>
For now the discount and the monopoly are the same thing.</p>

When Will Generic Wegovy Be Available?

2026-11-01T00:00:00+00:00

Apotex, a Canadian drugmaker, sells a weight-loss injection called Sevmia, and Health Canada says it “is a generic version of Wegovy.” Health Canada authorized it on June 29, 2026, as the country’s first generic semaglutide injection for weight loss. In India, generic semaglutide went on sale on March 21, 2026, the day after the core patent expired. Sun Pharmaceutical, Zydus Lifesciences and Alkem Laboratories already had Indian approval, since January, to sell generic versions of Wegovy and Ozempic. In China, Jiuyuan Genetic Biopharmaceutical has a generic Wegovy called Jikeqin under review by the regulator, which accepted the application in February 2026.</p>

So the answer to when will generic wegovy be available is: already, in several countries, and not for years in the United States. The US compound patent on semaglutide has been extended to December 5, 2031, and Novo Nordisk, which makes Wegovy, reports 2032 as the effective US compound expiry for Ozempic, Rybelsus and Wegovy. Behind that sits a stack of later patents, several specific to Wegovy and its new higher dose, running as late as 2041. Whether those later patents actually keep generics out is not settled, because patents get challenged and lawsuits get settled. But 2032 is the floor.</p>

Where generic Wegovy is already available</h2>
The Canadian story is mostly about a fee. Health Canada approved Dr. Reddy’s Laboratories’ generic semaglutide on April 28, 2026, the first G7 country to do so, because Novo Nordisk did not pay a CAD $250 maintenance fee in 2019 (roughly $180) and the patent lapsed permanently. That story has its own article on this site. Sevmia was the third generic semaglutide Health Canada approved, and the first one aimed at weight loss. Pen device patents in Canada are reported to run to at least 2033, which is a separate fight about the plastic part (it turns out the plastic part is also an invention).</p>
India is the big one. Before March 20, 2026, semaglutide in India came under exactly three brand names, Ozempic, Wegovy and Rybelsus, all from Novo. On day one, according to the Generic Guide, “more than a dozen manufacturers” launched. Dr. Reddy’s had announced in July 2025 that it planned to launch generic Wegovy in 87 countries in 2026. It’s fine. That is a normal number of countries.</p>

How patents keep generic Wegovy out of the US until at least 2032</h2>
Here is the chain, one link at a time. A drug company gets paid for a molecule by holding a patent on the molecule. US law lets it stretch that patent to make up for time lost in regulatory review, but only once: one patent term extension per active ingredient product. Wegovy is the same molecule as Ozempic (a fact the two brands’ marketing departments tend to mention quietly), so it cannot get a second extension on the same compound patent.</p>
That means the money from Wegovy (Novo’s obesity sales, driven largely by Wegovy, reached DKK 82.3 billion in 2025, roughly $12 billion) has to be protected some other way. The other way is more patents. I assume the internal meeting goes something like this, and I am making it up: “Okay, the molecule is spoken for. What else does it do?”</p>
It does a lot. There is US Patent 11,478,533, covering Wegovy and expiring May 13, 2040, whose official title is “Semaglutide For Use In Medicine.” Translated literally, this is a patent on using the medicine as medicine. There are two patents titled “Semaglutide in medical therapy” expiring October 10, 2038, and one titled “Semaglutide In Cardiovascular Conditions” expiring April 28, 2037. (My job consists largely of reading patent titles aloud and then rereading them more slowly, so I feel qualified to say these titles are doing a lot of work.)</p>
To be fair, this is how the system is built. The molecule patent is the expensive invention; the later patents are claims on specific uses, formulations and doses, and a generic company can try to work around them or knock them down. In Europe, Teva, Generics [UK] Limited and Galenicum Health challenged Novo’s obesity-treatment semaglutide patent in a European Patent Office case numbered T 1701/22. People fight these. How the US stack holds up is a question for lawyers and judges, and it has not been answered.</p>

What the higher-dose Wegovy HD adds to the timeline</h2>
On March 20, 2026, the FDA approved a 7.2 mg dose of Wegovy, branded Wegovy HD, for weight loss and long-term maintenance of weight loss in certain adults. That was also, by the calendar, the day India’s core semaglutide patent expired. I am sure this is a coincidence. FDA approval dates are notoriously hard to schedule.</p>
The higher dose comes with its own patent coverage. US Patent 11,318,191, titled “GLP-1 compositions and uses thereof,” covers Ozempic, Wegovy and Wegovy HD and expires February 17, 2041. A generic of the original 2.4 mg Wegovy might not need to copy the 7.2 mg version at all. But if the market moves to the new dose, the generic of the old dose is a generic of last season.</p>
This is the extended edition move, like a movie studio rereleasing a film with twenty more minutes. A made-up scenario, to be clear: Wegovy HD is followed in 2039 by Wegovy HD Plus at a higher dose, then Wegovy Ultra, then a 50 mg Wegovy Director’s Cut that comes in a commemorative pen, each with a fresh patent expiring fifteen years later, until the last generic company files its application for the 2.4 mg version in 2071 and discovers that the only remaining patients on 2.4 mg are its own employees. That will not happen. I guess the reason it will not happen is that doses are limited by what bodies tolerate, which is a better constraint than most in patent law.</p>

What happens to the price when the generics show up</h2>
India is the natural experiment. Before generic entry, Wegovy cost up to ₹16,400 a month (roughly $190). Generic semaglutide launched at ₹1,800 to ₹4,200 a month (roughly $20 to $50). Dr. Reddy’s had hoped to price its version up to 60% below Wegovy. Generic semaglutide took 50% of India’s semaglutide sales by value in April 2026.</p>
And then Novo cut its own prices: Ozempic by 36%, and the Wegovy starting dose by 48% on April 1, 2026, about ten days after the generics arrived. Look, between us, notice what that means. The price Novo charged in India on March 20 was not the lowest price at which Novo was willing to sell Wegovy in India. It was the highest price nobody could undercut.</p>
Is that dumb? Not really. A patent is a license to charge what the market will bear until someone else is allowed in, and then you charge what the new market will bear. The patent did exactly what it was designed to do, and so did its expiry.</p>

Where the chain ends up for American patients</h2>
In the US, no generic Wegovy has arrived, and the compound patent says none will before 2032. But prices have moved anyway. Novo and WeightWatchers offered one month of Wegovy at $299, a price also available through other telehealth partners until July 31, 2025. As of October 21, 2026, Novo’s own NovoCare Pharmacy lists self-pay Wegovy starting at $199 a month for the pen and $149 for the pill.</p>
Meanwhile, Novo told the US Department of Commerce, in a letter, that Chinese companies shipped enough semaglutide into the US in just over six months to make 1.5 billion starter doses of Wegovy. That is a separate world, the compounding one, and this site leaves it to others. I suppose the point is only that demand for cheap semaglutide in America did not politely wait for 2032.</p>
So follow the chain to the end. Novo gets paid for a molecule, protects the molecule, can only extend it once, patents the uses and the doses, cuts prices the moment generics land in India, and meanwhile sells discounted brand-name Wegovy to Americans who cannot buy the generic. Nobody designed the result.</p>
The cheapest Wegovy in America is Wegovy.</p>

When Will Ozempic Be Generic? The Dates, Country by Country

2026-11-01T00:00:00+00:00

I get asked when will Ozempic be generic about as often as people learn that I write about drug patents, which is to say rarely, but with real feeling. The plain answer is that it already is, in some countries, and will not be for years in others. Generic semaglutide (the molecule inside Ozempic) went on sale in India on March 21, 2026, and Health Canada approved its first generic version on April 28, 2026. In the United States, the core compound patent runs to December 5, 2031, and Novo Nordisk itself reports 2032 as the effective expiry.</p>

So the answer depends on where you live. The EU and UK are protected until about March 2031, and Japan until around 2031. China’s patent expired in March 2026, but a separate data protection rule keeps generics out until about April 2027. The research site Generic Guide put it this way as of September 2026: “generic semaglutide is on sale in India, Canada, Brazil, South Africa, and Saudi Arabia, but China and Mexico remain closed by data protection.” Same molecule. Different calendars.</p>

Start with one patent, then make it worse</h2>
Here is the reasonable version. You invent a useful molecule. The government says that for a set number of years nobody else can make it, and in exchange you publish how it works. When the time runs out, anyone can copy it and the price falls. That’s fine. It is a sensible bargain, and most people nod when they hear it.</p>
Now add one step. A drug takes years to get approved, and the patent clock runs that whole time while you sell nothing. So the government gives some of the time back. In plain words: you get to be the only seller for a while, and then, because the government was slow to let you start selling, you get to be the only seller a bit longer to make up for it. This is called patent term restoration, and it is why the US compound patent on semaglutide, US 8,129,343, runs to December 5, 2031.</p>
Another step. Patents are national. Each country grants its own, on its own schedule, with its own extensions (Europe calls its version a supplementary protection certificate, which is a very European name for a coupon). So one molecule can be expired in one country and protected next door. Messier, but still defensible.</p>
Another step. Even after the patent ends, a regulator may refuse, for some years, to let a copycat lean on the original company’s clinical trial data. That is data protection, a second lock on the same door. So a patent can die and nothing happens.</p>
Another step. Patents cost money to keep alive. Many countries charge periodic maintenance fees, and if you skip one, the patent lapses for good. So the monopoly on one of the most valuable drugs in the world could, in principle, end over an unpaid bill.</p>
The absurd endpoint: the answer to “when can anyone sell a cheap copy of this drug” becomes a function of your country, that country’s data rules, the shape of the injection pen, and whether a small payment went out in 2019. We are there. Every step.</p>

India: the patent ended and the generics arrived the next day</h2>
Novo Nordisk’s compound patent on semaglutide lapsed in India on March 20, 2026. Generic launches began March 21. More than 40 brands went on sale, with more than a dozen manufacturers launching on day one. Generic makers had been flirting with this market for a while (Sun Pharmaceutical, Zydus Lifesciences and Alkem Laboratories got Indian approval to manufacture and sell generic versions back in January 2026), and the relationship went public at the first legal opportunity. I like to imagine someone at a generic company saying “okay, everyone, tomorrow” on March 20 and meaning it literally, though I have no record of anyone saying that.</p>
The prices did what the textbook says. Ozempic had cost about ₹8,800 to ₹11,175 a month (roughly $105 to $135), and Wegovy up to ₹16,400. Generics came in at ₹1,800 to ₹4,200 a month (roughly $20 to $50). About ten days later, Novo Nordisk cut its Ozempic price in India by 36% and its Wegovy price by 48%. By April, generics had taken 50% of India’s semaglutide sales by value.</p>
People noticed, presumably.</p>
There is a catch, because there is always a catch. A formulation patent covering the absorption enhancer in the oral tablet runs to 2031 in India. So the injectable is generic and the pill is not. Same molecule, different stuff around it.</p>

Canada: the patent that ended over a fee</h2>
Canada is the step-five country. Novo Nordisk did not pay a 250 Canadian dollar maintenance fee (roughly $180) in 2019, and its patent, CA 2601784, lapsed permanently. Data protection ended January 4, 2026. Health Canada approved Dr. Reddy’s Laboratories’ generic semaglutide injection on April 28, 2026, and the agency’s own description is that Canada was “the first G7 country to approve a generic version of semaglutide.” Apotex got a second approval on May 1, 2026, a generic Ozempic for adults with type 2 diabetes, under the press-release headline “Apotex Becomes the First Canadian-Based Pharmaceutical Company to Receive Health Canada Approval for a Generic Equivalent of Ozempic.” Generic launches began from mid-May.</p>
For scale: Ozempic was Canada’s best-selling drug in 2025, with $2.9 billion in sales, more than three times the next drug on the list, and over a million Canadians were taking it when the generic was approved. A fairly popular product.</p>
You and I are both picturing the 2019 accounts-payable meeting. The facts say nothing about it, and why the fee went unpaid is not settled. It is the reverse of the gym membership you forgot to cancel: someone forgot to keep paying, and the membership actually ended.</p>
It is not a clean sweep, though. Pen device patents in Canada are reported to run to at least 2033, and Wegovy, the higher-dose obesity version, was reported as still patent-protected when Apotex’s approval came through. Patents are layered like that.</p>

China: the patent expired and nothing happened</h2>
China is the step-four country. The same compound patent expired there on March 20, 2026, the same day as India. But China’s data exclusivity runs to about April 2027, and as of October 2026, zero generic semaglutide products had been approved in mainland China. The patent is gone. The door is still locked.</p>
The generic makers are presumably standing outside it anyway. Dr. Reddy’s announced in July 2025 that it planned to launch generic Wegovy in 87 countries in 2026, beginning with Canada, India, Brazil and Turkey. China is a different calendar.</p>

When will Ozempic be generic in the US? 2031, or 2032, or later</h2>
The United States is every step at once. The compound patent is extended by restoration to December 5, 2031. Novo Nordisk said in its 2025 annual filing that the effective US compound expiry for Ozempic, Rybelsus and Wegovy is 2032. DrugPatentWatch also says 2032, which conflicts with the December 2031 date. Which one governs in practice is not settled by these facts, and the gap is about a month, so it may not matter much (or it may matter a lot to whoever wants to launch on day one).</p>
Then come the secondary patents. US patents tied to Ozempic run to 2031, 2034 and 2037, covering oral dosing, solid compositions with absorption enhancers and the injection pen, with secondary protection reaching as far as 2038. Rybelsus, the pill, has an estimated US generic launch date of May 2, 2034. Whether a generic injection can launch in 2032 without tripping over a pen patent is the kind of thing lawyers get paid to argue about, and the facts here do not say how that argument ends.</p>
Meanwhile the generic is, in some sense, already approved. On April 10, 2026, Apotex received the first US FDA tentative approval for a generic Ozempic. Tentative approval means the FDA has reviewed the product and is satisfied with it, but it cannot be sold until the patents allow. It is the regulator saying “this looks great, please wait five years,” lol.</p>
I mean, the system is working as designed. Each step was reasonable when someone added it. Stack them up, though, and a type 2 diabetes patient in Toronto and one in Toledo are on opposite sides of a 2019 invoice, a December 2031 extension and a pen.</p>
A patent is a fact about a place, not about a molecule.</p>